{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:09:51Z","timestamp":1792026591059,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011535.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000}}],"reference-count":1085,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011535.pub5","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T10:50:27Z","timestamp":1653303027000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Department of Dermatology; H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Clinical Investigation Centre; H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France"},{"name":"Cochrane France; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garcia-Doval","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Complexo Hospitalario Universitario de Vigo; Vigo Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Doney","sequence":"additional","affiliation":[{"name":"Cochrane Skin, Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Dressler","sequence":"additional","affiliation":[{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin; Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Dermatology; H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Hughes","sequence":"additional","affiliation":[{"name":"c\/o Cochrane Skin Group; The University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[{"name":"Centro Studi GISED (Italian Group for Epidemiologic Research in Dermatology) - FROM (Research Foundation of Ospedale Maggiore Bergamo); Padiglione Mazzoleni - Presidio Ospedaliero Matteo Rota; Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivem","family":"Afach","sequence":"additional","affiliation":[{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Le Cleach","sequence":"additional","affiliation":[{"name":"Department of Dermatology; H\u00f4pital Henri Mondor; Cr\u00e9teil France"},{"name":"Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Universit\u00e9 Paris Est Cr\u00e9teil (UPEC); Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/eci.10.92","article-title":"The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients","volume":"7","author":"Young","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0003|cit3","first-page":"A301","article-title":"Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab","volume":"5","author":"Blauvelt","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0005|cit5","unstructured":"Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and humira (ADACCESS) clinicaltrials.gov\/show\/nct02016105"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0300060514539280","article-title":"Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis","volume":"42","author":"Akcali","year":"2014","journal-title":"Journal of International Medical Research"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/ijd.12444","article-title":"Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis","volume":"53","author":"Al-Hamamy","year":"2014","journal-title":"International Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0008|cit8","unstructured":"Study of efficacy and safety of secukinumab 2 mL pre-filled syringe (300 mg) in subjects with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-005170-38-BE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0009|cit9","unstructured":"Study of secukinumab with 2 mL pre-filled syringes (ALLURE) clinicaltrials.gov\/ct2\/show\/NCT02748863"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0010|cit10","unstructured":"Sigurgeirsson B Sch\u00e4kel K Hong CH Effendy I Placek W Rich P Efficacy, tolerability, patient usability, and satisfaction with a 2\u2009mL pre-filled syringe containing secukinumab 300\u2009mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study Journal of Dermatological Treatment 10.1080\/09546634.2021.1902925"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14712598.2021.1843629","article-title":"A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis","volume":"21","author":"AlMutairi","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5114\/ada.2019.91496","article-title":"Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature","volume":"38","author":"AlMutairi","year":"2021","journal-title":"Postepy Dermatologii i Alergologii"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"AB164","DOI":"10.1016\/j.jaad.2020.06.743","article-title":"15921 Absolute PASI response up to 52 weeks with brodalumab in patients with moderate to severe plaque psoriasis","volume":"83 6 Suppl","author":"Armstrong","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized,double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","article-title":"Dermatology Life Quality Index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab","volume":"11","author":"Lambert","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0017|cit17","first-page":"S26","article-title":"Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis: data from a pivotal Phase III clinical trial","volume":"11","author":"Menter","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0018|cit18","first-page":"S23","article-title":"Maintenance of clinical efficacy in moderate-to-severe plaque psoriasis: a 52-week evaluation of brodalumab in three multicenter, double-blind studies of 4363 subjects","volume":"10","author":"Papp","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II\/III randomized controlled study","volume":"37","author":"Asahina","year":"2010","journal-title":"Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2006.01.004","article-title":"Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study","volume":"54","author":"Asawanonda","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjd.18220","article-title":"AURIEL-PsO: a randomised, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"182","author":"Hercogova","year":"2020","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0023|cit23","unstructured":"MSB11022 in moderate to severe chronic plaque psoriasis (AURIEL-PsO) clinicaltrials.gov\/show\/nct02660580"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study","volume":"30","author":"Valenzuela","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0026|cit26","first-page":"AB150","article-title":"Etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp","volume":"64","author":"Bagel","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0030|cit30","unstructured":"Study to evaluate safety and efficacy of different doses of bimekizumab in patients with chronic plaque psoriasis (BE ABLE 1) clinicaltrials.gov\/show\/nct02905006"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0032|cit32","unstructured":"A study to evaluate the efficacy and safety of bimekizumab compared to an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE RADIANT) clinicaltrials.gov\/show\/nct03536884"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"AB139","DOI":"10.1016\/j.jaad.2021.06.573","article-title":"27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial","volume":"85 (3 Suppl)","author":"Blauvelt","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10273","key":"10.1002\/14651858.CD011535.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0036|cit36","unstructured":"A study with an initial treatment period followed by a randomized-withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE READY) clinicaltrials.gov\/show\/nct03410992"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0037|cit37","unstructured":"A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE SURE) clinicaltrials.gov\/show\/nct03412747"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0038|cit38","first-page":"S21","article-title":"Bimekizumab efficacy and safety versus adalimumab in patients with moderate-to-severe plaque psoriasis: results from a multicenter, randomized, double-blinded active comparator-controlled phase III trial (BE SURE)","volume":"14 (5 Suppl 1)","author":"Warren","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0040|cit40","first-page":"S23","article-title":"Bimekizumab versus ustekinumab in plaque psoriasis: lasting efficacy translates to rapid and sustained improvements in quality of life in the BE VIVID multicenter, randomized, double-blinded Phase III trial","volume":"14 5 Suppl 1","author":"Gordon","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0041|cit41","unstructured":"A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE VIVID) clinicaltrials.gov\/show\/nct03370133"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0042|cit42","first-page":"S22","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID Phase III trial","volume":"14 5 Suppl 1","author":"Papp","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"10273","key":"10.1002\/14651858.CD011535.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0044|cit44","first-page":"83","article-title":"Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial","volume":"6","author":"Bissonnette","year":"2013","journal-title":"Circulation: Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0045|cit45","unstructured":"Blauvelt A Gordon KB Lee P Bagel J Sofen H Lockshin B Efficacy, safety, usability, and acceptability of risankizumab 150\u2009mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis Journal of Dermatological Treatment 10.1080\/09546634.2021.1914812"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0046|cit46","unstructured":"A study to assess safety and efficacy of risankizumab using a new formulation in participants with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct03875482"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae - and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.15922","article-title":"Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study","volume":"34","author":"Van de Kerkhof","year":"2020","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.15922","article-title":"Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study","volume":"34","author":"Van de Kerkhof","year":"2020","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0051|cit51","first-page":"AB445","article-title":"Secukinumab 300 mg showed faster and higher efficacy in Chinese moderate to severe plaque psoriasis patients","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"22","key":"10.1002\/14651858.CD011535.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0053|cit53","unstructured":"Study of efficacy and safety of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis clinicaltrials.gov\/show\/nct03066609"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0054|cit54","unstructured":"A randomised, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis comorbidity www.thaiclinicaltrials.org\/show\/TCTR20161028001"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0055|cit55","unstructured":"Comparative double-blind study of the efficacy and safety of BCD-057 and Humira\u00ae in patients with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2018\/03\/012598"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14412\/1996-7012-2018-4-71-84","article-title":"Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2\/CALYPSO phase III international, multicenter, randomized double-blind clinical trial","volume":"12","author":"Korotaeva","year":"2018","journal-title":"Modern Rheumatology Journal"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0057|cit57","unstructured":"Comparative clinical trial of efficacy and safety of BCD-057 and Humira\u00ae in patients with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct02762955"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","article-title":"Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial","volume":"29","author":"Caproni","year":"2009","journal-title":"Journal of Clinical Immunology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0059|cit59","unstructured":"Evaluation of cardiovascular risk markers in psoriasis patients treated with secukinumab (CARIMA) clinicaltrials.gov\/ct2\/show\/NCT02559622"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"Von Stebut","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0061|cit61","first-page":"554","article-title":"Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis","volume":"13","author":"Navarini","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0062|cit62","first-page":"864","article-title":"Efficacy of adalimumab compared with methotrexate or placebo stratified by baseline BMI in a randomized placebo-controlled trial in patients with psoriasis","volume":"14","author":"Prussick","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","article-title":"Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial","volume":"63","author":"Reich","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","article-title":"Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","volume":"165","author":"Saurat","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0067|cit67","unstructured":"A trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct03331835"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0068|cit68","first-page":"16","article-title":"A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"16","author":"Pinter","year":"2020","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdv.16932","article-title":"A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)","volume":"35","author":"Pinter","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"9271","key":"10.1002\/14651858.CD011535.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mjd.2003.10","article-title":"Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris","volume":"48","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1742-7843.2005.pto960318.x","article-title":"Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis","volume":"96","author":"Chladek","year":"2005","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0075|cit75","unstructured":"Efficacy and safety study of certolizumab pegol (CZP) versus active comparator and placebo in subjects with plaque psoriasis (PSO) (CIMPACT) clinicaltrials.gov\/ct2\/show\/NCT02346240"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0077|cit77","unstructured":"An efficacy and safety study of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) clinicaltrials.gov\/show\/nct02326298"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0079|cit79","unstructured":"A study to evaluate the efficacy and safety of two dose levels of certolizumab pegol (CZP) in subjects with plaque psoriasis (PSO) (CIMPASI-2) clinicaltrials.gov\/ct2\/show\/NCT02326272"},{"issue":"4 Supp 1","key":"10.1002\/14651858.CD011535.pub5-BIB0080|cit80","first-page":"AB274","article-title":"Secukinumab is superior to ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: CLARITY, a randomized, controlled, phase 3b trial","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0081|cit81","unstructured":"Bagel J Blauvelt A Nia J Hashim P Patekar M de Vera A Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) Journal of the European Academy of Dermatology & Venereology 10.1111\/jdv.16558"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.16558","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","volume":"35","author":"Bagel","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0083|cit83","first-page":"S27","article-title":"Secukinumab is superior to ustekinumab in clearing skin of patients with moderate-to-severe plaque psoriasis: CLARITY, a randomized, controlled, Phase IIIb trial","volume":"11","author":"Bagel","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","article-title":"Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results)","volume":"8","author":"Bagel","year":"2018","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0085|cit85","unstructured":"Study of secukinumab compared to ustekinumab in subjects with plaque psoriasis (CLARITY) clinicaltrials.gov\/ct2\/show\/NCT02826603"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0086|cit86","first-page":"S15","article-title":"Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis","volume":"10","author":"Blauvelt","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/jdv.14391","article-title":"Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study","volume":"31","author":"Blauvelt","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0089|cit89","first-page":"S18","article-title":"Secukinumab 300mg is more efficacious than ustekinumab 90mg: analysis of the CLEAR study","volume":"10","author":"Herranz Pinto","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0090|cit90","first-page":"86","article-title":"Secukinumab 300 mgs is more efficacious than ustekinumab 90 mgs: analysis of patients with body weights over 100kg from the CLEAR study","volume":"58","author":"Spelman","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0091|cit91","first-page":"S17","article-title":"Secukinumab delivers greater improvement in health-related quality of life compared to ustekinumab in subjects with moderate-to-severe plaque psoriasis: 16-week data from the CLEAR study","volume":"9","author":"Tha\u00e7i","year":"2016","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2230.2012.04440.x","article-title":"Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study","volume":"37","author":"Dogra","year":"2012","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"146 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0095|cit95","first-page":"136","article-title":"Cyclosporin in psoriasis. A long-term randomized study on 37 patients","volume":"69","author":"Dubertret","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0096|cit96","first-page":"S24","article-title":"Guselkumab demonstrates greater efficacy compared to secukinumab across body weight quartiles and body mass index categories: week 48 results from the ECLIPSE trial","volume":"12","author":"Armstrong","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0097|cit97","first-page":"58","article-title":"Consistent responses to guselkumab by disease region at week 48 in the treatment of moderate-to-severe psoriasis: ECLIPSE trial results","volume":"62 Suppl 1","author":"Langley","year":"2021","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"AB34","DOI":"10.1016\/j.jaad.2020.06.225","article-title":"15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: findings from the ECLIPSE study","volume":"83 6 Suppl","author":"Langley","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0099|cit99","unstructured":"A study to evaluate the comparative efficacy of CNTO 1959 (guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE) clinicaltrials.gov\/show\/nct03090100"},{"issue":"10201","key":"10.1002\/14651858.CD011535.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jdv.14605","article-title":"Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study","volume":"32","author":"Gerdes","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.jid.2017.07.098","article-title":"Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis","volume":"137","author":"Griffiths","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0104|cit104","unstructured":"Study to demonstrate equivalent efficacy and to compare safety of biosimilar etanercept (GP2015) and Enbrel (EGALITY) clinicaltrials.gov\/show\/nct01891864"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1136\/annrheumdis-2017-eular.2148","article-title":"Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","volume":"76","author":"Elewski","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0107|cit107","first-page":"26","article-title":"Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","volume":"98","author":"Elewski","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD011535.pub5-BIB0108|cit108","first-page":"65","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase-3, randomized, placebo-controlled trial","volume":"30","author":"Elewski","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0110|cit110","first-page":"188","article-title":"Long-term cyclosporin A for psoriasis","volume":"3","author":"Engst","year":"1994","journal-title":"Acta Dermatovenerologica Alpina, Panonica et Adriatica"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0111|cit111","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/1346-8138.12668","article-title":"Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study","volume":"41","author":"Ohtsuki","year":"2014","journal-title":"Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2016.02.1164","article-title":"Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis","volume":"75","author":"Bissonnette","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"9494","key":"10.1002\/14651858.CD011535.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial","volume":"154","author":"Reich","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","article-title":"Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis","volume":"159","author":"Feldman","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0122|cit122","first-page":"381","article-title":"Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis","volume":"17","author":"Reich","year":"2007","journal-title":"European Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000317775","article-title":"Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS trial","volume":"221","author":"Reich","year":"2010","journal-title":"Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2133.2010.10195.x","article-title":"Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial","volume":"164","author":"Fallah Arani","year":"2011","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0125|cit125","unstructured":"A comparison of the efficacy of oral fumarate and methotrexate therapy in the treatment of severe psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN76608307"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0128|cit128","first-page":"116","article-title":"Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial","volume":"158","author":"Flytstr\u00f6m","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial","volume":"158","author":"Gisondi","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0190-9622(88)70086-9","article-title":"Acitretin improves psoriasis in a dose-dependent fashion","volume":"18","author":"Goldfarb","year":"1988","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta","year":"1989","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","article-title":"Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial","volume":"18","author":"Shikiar","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"27","author":"Shikiar","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4274\/turkderm.54771","article-title":"A single-blind study comparing acitretin and narrow-band UVB with the combination of placebo and narrow-band UVB in the treatment of plaque-type psoriasis","volume":"49","author":"Gurel","year":"2015","journal-title":"T\u00fcrkderm"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archderm.140.6.685","article-title":"Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine","volume":"140","author":"Opmeer","year":"2004","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1440-0960.1963.tb01685.x","article-title":"Methotrexate in the treatment of psoriasis: a controlled clinical trial","volume":"7","author":"Hunter","year":"1963","journal-title":"Australasian Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1346-8138.2012.01521.x","article-title":"Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2\/3 trial","volume":"39","author":"Nakagawa","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"e006283","DOI":"10.1161\/CIRCIMAGING.117.006283","article-title":"Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor - a antagonism or cyclosporine in psoriasis","volume":"10","author":"Ikonomidis","year":"2017","journal-title":"Circulation. Cardiovascular imaging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0148|cit148","first-page":"688","article-title":"Greater improvement of coronary artery function, left ventricular deformation and twisting by treatment with IL-17A antagonist compared to cyclosporine in psoriasis","volume":"38","author":"Ikonomidis","year":"2017","journal-title":"European Heart Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub5-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"iii341","DOI":"10.1093\/ehjci\/jex298","article-title":"Treatment with IL-17A antagonist results in a greater improvement of coronary artery function, left ventricular deformation and twisting than cyclosporine in psoriasis","volume":"18","author":"Ikonomidis","year":"2017","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0150|cit150","unstructured":"Risankizumab versus secukinumab for subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct03478787"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0153|cit153","first-page":"18","article-title":"Efficacy and safety of risankizumab, an IL-23 inihibitor in patients with moderate-to-severe chronic plaque psoriasis: 16-week phase 3 IMMhance trial results","volume":"16","author":"Blauvelt","year":"2018","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0154|cit154","first-page":"e248","article-title":"Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial","volume":"177","author":"Blauvelt","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0155|cit155","first-page":"30","article-title":"Risankizumab efficacy\/safety in moderate-to-severe plaque psoriasis: 16-week results from IMMhance","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0156|cit156","unstructured":"BI 655066\/ABBV-066 (Risankizumab) in moderate to severe plaque psoriasis with randomized withdrawal and re-treatment clinicaltrials.gov\/ct2\/show\/NCT02672852"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0157|cit157","unstructured":"BI 655066 (risankizumab) versus adalimumab in a randomised, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and after inadequate adalimumab treatment response (IMMvent) - BI 655066 (risankizumab) versus adalimumab www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number%3A2015-003623-65\/EUCTR2015-003623-65"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0158|cit158","unstructured":"BI 655066\/ABBV-066 (risankizumab) compared to active comparator (adalimumab) in patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct02694523"},{"issue":"10198","key":"10.1002\/14651858.CD011535.pub5-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0161|cit161","unstructured":"A study comparing different dosing regimens of ixekizumab (LY2439821) in participants with moderate to severe plaque psoriasis (IXORA-P) clinicaltrials.gov\/ct2\/show\/NCT02513550"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0162|cit162","first-page":"44","article-title":"Absolute and relative pasi improvements with ixekizumab treatment: results at week 12 from IXORA-P","volume":"98","author":"Papp","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0163|cit163","unstructured":"Blauvelt A Leonardi C Elewski B Crowley JJ Guenther LC Gooderham M A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial British Journal of Dermatology 10.1111\/bjd.19509"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"AB19","DOI":"10.1016\/j.jaad.2020.06.163","article-title":"14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis","volume":"83 6 Suppl","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0167|cit167","first-page":"S20","article-title":"A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate to severe plaque psoriasis: 12-week efficacy, safety, and speed of response from a randomized, double-blind trial","volume":"12","author":"Blauvelt","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.jid.2021.02.679","article-title":"649 Validation of the Optimal Psoriasis Assessment Tool (OPAT) as a method of assessing psoriasis severity and impact from physician and patient perspectives","volume":"141 5 Suppl","author":"Leonardi","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0169|cit169","unstructured":"A study of ixekizumab (LY2439821) compared to guselkumab in participants with moderate-to-severe plaque psoriasis (IXORA-R) clinicaltrials.gov\/show\/nct03573323"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0170|cit170","first-page":"AB113","article-title":"Rapid clinical response predicts consistent long-term response in patients with moderate-to-severe psoriasis: Ixekizumab vs. ustekinumab","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0171|cit171","first-page":"55","article-title":"Ixekizumab provides greater cumulative benefits versus ustekinumab over 24 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blind phase 3b clinical trial","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","article-title":"Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial","volume":"31","author":"Blauvelt","year":"2020","journal-title":"Journal of Dermatological Treatment"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0173|cit173","first-page":"A902","article-title":"Ixekizumab treatment leads to early resolution of bothersome symptoms versus ustekinumab","volume":"20","author":"Burge","year":"2017","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0174|cit174","first-page":"43","article-title":"Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: a randomised head-to-head trial","volume":"58","author":"Burkhardt","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0175|cit175","first-page":"41","article-title":"Comparison of ixekizumab with ustekinumab in patients with baseline PASI > 15 and\/or at-least 3-previous-non-biologic-therapies-treatment-failures: 24-week post-hoc-analysis from a randomized trial (IXORA-S;NCT02561806)","volume":"59","author":"Burkhardt","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0176|cit176","first-page":"1827","article-title":"Comparison of ixekizumab and ustekinumab efficacy in the treatment of nail lesions of patients with moderate-to-severe plaque psoriasis: 24-week data from a phase 3 trial","volume":"69","author":"Ghislain","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0177|cit177","unstructured":"A study of Ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis clinicaltrials.gov\/ct2\/show\/NCT02561806"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","article-title":"Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study","volume":"80","author":"Paul","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jid.2018.03.484","article-title":"Consistency of response across subgroups of patients with moderate-to-severe plaque psoriasis following 52 weeks of treatment with ixekizumab compared to ustekinumab","volume":"138","author":"Paul","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0180|cit180","first-page":"e293","article-title":"52-week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Paul","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"19","key":"10.1002\/14651858.CD011535.pub5-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3700","article-title":"An analysis of patient-reported outcomes in ixora-s: comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis","volume":"100","author":"Puig","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jdv.14073","article-title":"Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial","volume":"31","author":"Lacour","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"S6","key":"10.1002\/14651858.CD011535.pub5-BIB0185|cit185","first-page":"73","article-title":"Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis","volume":"30","author":"Khatri","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0186|cit186","first-page":"33","article-title":"Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis","volume":"11","author":"Khattri","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte","year":"1994","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","article-title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaad.2005.06.053","article-title":"Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial","volume":"53","author":"Feldman","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"Journal of Dermatological Treatment"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.jaad.2005.10.054","article-title":"Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial","volume":"54","author":"Krueger","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"21","key":"10.1002\/14651858.CD011535.pub5-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jdv.13032","article-title":"A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab","volume":"30","author":"Edson-Heredia","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2014.07.048","article-title":"A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis","volume":"71","author":"Gordon","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"13","key":"10.1002\/14651858.CD011535.pub5-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jcph.312","article-title":"Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis","volume":"54","author":"Tham","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bjd.12610","article-title":"Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis","volume":"169","author":"Zhu","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/bjd.13065","article-title":"Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial","volume":"171","author":"Zhu","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept, and placebo, in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00403-019-02024-6","article-title":"Etanercept biosimilar (recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial","volume":"312","author":"Liu","year":"2020","journal-title":"Archives of Dermatological Research"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0204|cit204","unstructured":"Optimizing psoriasis treatment of etanercept combined methotrexate clinicaltrials.gov\/ct2\/show\/NCT02313922"},{"issue":"s1","key":"10.1002\/14651858.CD011535.pub5-BIB0205|cit205","first-page":"238","article-title":"A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results","volume":"39","author":"Zheng","year":"2012","journal-title":"Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0206|cit206","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0207|cit207","first-page":"521","article-title":"Ustekinumab improves health-related quality of life in Chinese patients with moderate-to-severe plaque psoriasis: results from the LOTUS trial and curative effect observation","volume":"43","author":"Zheng","year":"2014","journal-title":"Journal of Clinical Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0190-9622(91)70089-K","article-title":"Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone","volume":"24","author":"Lowe","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis - a randomized single-blinded placebo-controlled study","volume":"24","author":"Mahajan","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2340\/0001555577137141","article-title":"Low-dose (1.25 mg\/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile","volume":"77","author":"Meffert","year":"1997","journal-title":"Acta Dermato-Venereologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjd.18001","article-title":"Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways","volume":"181","author":"Reich","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"10068","key":"10.1002\/14651858.CD011535.pub5-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"Journal of Dermatological Science"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jdv.13785","article-title":"Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis","volume":"30","author":"Umezawa","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0215|cit215","first-page":"2142","article-title":"Randomized, double-blind study comparing CHS-0214 with etanercept (ENBREL) in patients with psoriasis and psoriatic arthritis","volume":"68","author":"Kivitz","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"AB128","DOI":"10.1016\/j.jaad.2017.04.500","article-title":"Evaluation of CHS-0214 as a proposed biosimilar to etanercept for the treatment of chronic plaque psoriasis: one-year results from a randomized, double-blind global trial","volume":"76","author":"Leonardi","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0217|cit217","unstructured":"Comparison of CHS-0214 to Enbrel (etanercept) in patients with chronic plaque psoriasis (PsO) clinicaltrials.gov\/show\/nct02134210"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0218|cit218","unstructured":"Phase 3 study of M923 and Humira\u00ae in subjects with chronic plaque-type psoriasis clinicaltrials.gov\/show\/nct02581345"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0219|cit219","unstructured":"International clinical trial to evaluate efficacy and safety of multiple subcutaneous injections of BCD-085 in various doses in patients with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct02762994"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaad.2020.06.239","article-title":"15354 Response to treatment with secukinumab in obese patients with moderate to severe psoriasis","volume":"83 (6 Suppl)","author":"Krueger","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"AB37","DOI":"10.1016\/j.jaad.2020.06.234","article-title":"15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis","volume":"83 (6 Suppl)","author":"Krueger","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0222|cit222","unstructured":"Study to explore the effect of secukinumab, compared to placebo, on fat tissue and skin in plaque psoriasis patients (ObePso-S) clinicaltrials.gov\/show\/nct03055494"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0223|cit223","unstructured":"A study of ixekizumab (LY2439821) in Chinese participants with moderate-to-severe plaque psoriasis clinicaltrials.gov\/show\/nct03364309"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"AB55","DOI":"10.1016\/j.jaad.2021.06.246","article-title":"25258 Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study","volume":"85 (3 Suppl)","author":"Rui","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0225|cit225","unstructured":"A study to assess the efficacy and safety of PPC-06 (tepilamide fumarate) clinicaltrials.gov\/show\/nct03421197"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0226|cit226","unstructured":"Efficacy and safety of 2 secukinumab regimens in 90 kg or higher subjects with moderate to severe chronic plaque-type psoriasis clinicaltrials.gov\/show\/nct03504852"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0227|cit227","unstructured":"A study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate to severe plaque psoriasis (OASIS-2) clinicaltrials.gov\/show\/nct03535194"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0228|cit228","first-page":"S26","article-title":"Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study","volume":"14 (5 Suppl)","author":"Papp","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0229|cit229","unstructured":"Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) injections in subjects with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-000518-39-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0230|cit230","unstructured":"Study of efficacy and safety of secukinumab 2 mL auto-injector (300 mg) in subjects with moderate to severe plaque psoriasis (MATURE) clinicaltrials.gov\/show\/nct03589885"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"AB154","DOI":"10.1016\/j.jaad.2021.06.630","article-title":"27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE","volume":"85 (3 Suppl)","author":"Sigurgeirsson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"49","key":"10.1002\/14651858.CD011535.pub5-BIB0232|cit232","first-page":"2387","article-title":"Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study","volume":"134","author":"Nugteren-Huying","year":"1990","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(08)80766-9","article-title":"Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study","volume":"22","author":"Nugteren-Huying","year":"1990","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0234|cit234","first-page":"10","article-title":"Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: results from a phase 2b randomized trial","volume":"10","author":"Imafuku","year":"2020","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0235|cit235","unstructured":"Efficacy and safety study of two doses of Apremilast (CC-10004) in Japanese subjects with moderate-to-severe plaque-type psoriasis clinicaltrials.gov\/ct2\/show\/NCT01988103"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1346-8138.13829","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0237|cit237","unstructured":"An efficacy and safety of CNTO 1959 (Guselkumab) in participants with moderate to severe plaque-type psoriasis clinicaltrials.gov\/ct2\/show\/NCT02325219"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.14504","article-title":"Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"Journal of Dermatology"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0190-9622(89)70236-X","article-title":"A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis","volume":"21","author":"Olsen","year":"1989","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0240|cit240","article-title":"Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: results from the phase III Orion self-dose study through week 16","volume":"12","author":"Ferris","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0241|cit241","first-page":"29","article-title":"Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: results from the phase III ORION self-dose study through week 16","volume":"98","author":"Ferris","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","article-title":"Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study","volume":"31","author":"Ferris","year":"2020","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0243|cit243","unstructured":"Efficacy and safety study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis clinicaltrials.gov\/ct2\/show\/NCT02905331"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","article-title":"Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial","volume":"153","author":"Krueger","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjd.12636","article-title":"Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory","volume":"170","author":"Gordon","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","article-title":"Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment","volume":"71","author":"Papp","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","article-title":"Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis","volume":"72","author":"Papp","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"13","key":"10.1002\/14651858.CD011535.pub5-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9843","key":"10.1002\/14651858.CD011535.pub5-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-11-82","article-title":"Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study","volume":"10","author":"Strand","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jdv.12343","article-title":"Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and\/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study","volume":"28","author":"Sigurgeirsson","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1111\/j.1468-3083.2012.04716.x","article-title":"Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study","volume":"27","author":"Papp","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0257|cit257","unstructured":"Study to compare efficacy and safety of ABP 501 and adalimumab (HUMIRA\u00ae) in adults with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct01970488"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0259|cit259","unstructured":"BI 655066 dose ranging in psoriasis, active comparator ustekinumab clinicaltrials.gov\/ct2\/show\/NCT02054481"},{"issue":"16","key":"10.1002\/14651858.CD011535.pub5-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0261|cit261","first-page":"55","article-title":"A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis","volume":"27","author":"Catlett","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0262|cit262","article-title":"A selective inhibitor of tyrosine kinase 2, bms-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis","volume":"12","author":"Catlett","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association (Conference: 24th World Congress of Dermatology, Italy)"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0263|cit263","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-002481-31-LV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0264|cit264","first-page":"32","article-title":"Influence of baseline demographics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis: a Phase 2, randomized, placebo-controlled trial","volume":"27","author":"Gooderham","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0265|cit265","first-page":"29","article-title":"Evaluating influence of baseline characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial","volume":"27","author":"Gordon","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0266|cit266","first-page":"907","article-title":"Influence of baseline demographics and disease characteristics on efficacy of an oral, selective TYK2 inhibitor, BMS-986165, in patients with plaque psoriasis in a phase 2 trial","volume":"78","author":"Gordon","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0267|cit267","unstructured":"Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis clinicaltrials.gov\/show\/nct02931838"},{"issue":"14","key":"10.1002\/14651858.CD011535.pub5-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"S3","key":"10.1002\/14651858.CD011535.pub5-BIB0269|cit269","first-page":"71","article-title":"Selective oral tyrosine kinase 2 (TYK2) inhibitor (BMS-986165) impact on quality of life (QOL) in patients with moderate to severe plaque psoriasis (PSO) in a phase 2 trial as assessed by the dermatology life quality index (DLQI)","volume":"33","author":"Tha\u00e7i","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0270|cit270","first-page":"S26","article-title":"An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves health-related quality of life in psoriasis: results from a phase II trial","volume":"12","author":"Thaci","year":"2020","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0271|cit271","unstructured":"A phase 2b study of the efficacy, safety, and tolerability of M1095 in subjects with moderate to severe psoriasis clinicaltrials.gov\/show\/nct03384745"},{"issue":"10284","key":"10.1002\/14651858.CD011535.pub5-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"Journal of Dermatological Science"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0274|cit274","first-page":"943","article-title":"Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial","volume":"11","author":"Tsai","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1468-3083.2011.04082.x","article-title":"Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials","volume":"25","author":"Guenther","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10928-011-9191-7","article-title":"Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis","volume":"38","author":"Hu","year":"2011","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"9625","key":"10.1002\/14651858.CD011535.pub5-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0283|cit283","first-page":"300","article-title":"An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up","volume":"11","author":"Reich","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhou","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"9625","key":"10.1002\/14651858.CD011535.pub5-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/09546634.2010.499931","article-title":"Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2","volume":"22","author":"Reich","year":"2011","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bjd.14867","article-title":"A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study","volume":"176","author":"De Vries","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00403-002-0353-8","article-title":"Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ","volume":"294","author":"Piskin","year":"2003","journal-title":"Archives of Dermatological Research"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0293|cit293","article-title":"Netakimab: 12-week results from Planeta study, a phase III trial of a novel il-17 inhibitor in moderate-to-severe plaque psoriasis","volume":"12","author":"Andrey","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0295|cit295","first-page":"31","article-title":"Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"31","author":"Puig","year":"2021","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0296|cit296","unstructured":"A study to compare the efficacy of guselkumab to fumaric acid esters for the treatment of participants with moderate to severe plaque psoriasis (POLARIS) clinicaltrials.gov\/ct2\/show\/NCT02951533"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0297|cit297","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjd.18696","article-title":"Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are na\u00efve to systemic treatment: results from a randomised, active comparator-controlled phase 3b trial (POLARIS)","volume":"183","author":"Tha\u00e7i","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/09546634.2017.1329509","article-title":"Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe","volume":"29","author":"Damjanov","year":"2018","journal-title":"Journal of Dermatological Treatment"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","article-title":"Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens","volume":"26","author":"Gniadecki","year":"2012","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjd.13139","article-title":"Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept","volume":"172","author":"Griffiths","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0301|cit301","first-page":"11","article-title":"Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial","volume":"33","author":"Kirkham","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1468-3083.2010.03838.x","article-title":"Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial","volume":"25","author":"Prinz","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0304|cit304","unstructured":"Study of secukinumab compared to fumaderm\u00ae in adults with moderate to severe psoriasis (PRIME) clinicaltrials.gov\/ct2\/show\/NCT02474082"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.15707","article-title":"Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial","volume":"177","author":"Sticherling","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/09546634.2013.860209","article-title":"Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis","volume":"26","author":"Puig","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09546634.2012.658015","article-title":"The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)","volume":"24","author":"Strohal","year":"2013","journal-title":"Journal of Dermatological Treatment"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/jdv.12207","article-title":"Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial","volume":"28","author":"Tha\u00e7i","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0309|cit309","unstructured":"A study to compare the efficacy and safety of CHS-1420 against Humira\u00ae www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-000632-15-EE"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0310|cit310","first-page":"2879","article-title":"Switching from adalimumab to CHS-1420: a randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis","volume":"69","author":"Hodge","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0311|cit311","unstructured":"Comparison of CHS-1420 versus Humira in subjects with chronic plaque psoriasis (PsOsim) clinicaltrials.gov\/show\/nct02489227"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0312|cit312","unstructured":"A study to assess the effects of apremilast and methotrexate in the treatment of patients with psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2019\/01\/017362"},{"issue":"15","key":"10.1002\/14651858.CD011535.pub5-BIB0313|cit313","first-page":"231517","article-title":"An open-labelled randomised comparative evaluation of therapeutic efficacy and safety of apremilast versus methotrexate in the treatment of patients with chronic plaque psoriasis","volume":"23","author":"Rathipriyadharshini","year":"2020","journal-title":"Annals of Tropical Medicine and Public Health"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.19558","article-title":"Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"184","author":"Leutz","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0317|cit317","unstructured":"A study of Ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis naive to systemic treatment clinicaltrials.gov\/ct2\/show\/NCT02325219"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjd.18384","article-title":"A 24-week multicentre, randomised, open-label, parallel-group study comparing the efficacy and safety of ixekizumab to fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis na\u00efve to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub5-BIB0319|cit319","first-page":"230","article-title":"Erratum: Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (Lancet 2017; 390(10091):276-288)","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0320|cit320","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0321|cit321","unstructured":"A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-010) clinicaltrials.gov\/ct2\/show\/NCT01722331"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0322|cit322","first-page":"110","article-title":"Safety and tolerability of tildrakizumab in patients with chronic plaque psoriasis: esults from long-term extensions of 2 phase 3 studies","volume":"59","author":"Reich","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub5-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0324|cit324","unstructured":"A study to evaluate the efficacy and safety\/tolerability of subcutaneous tildrakizumab (SCH 900222\/MK-3222) in participants with moderate-to-severe chronic plaque psoriasis followed by a long-term extension study (MK-3222-011) clinicaltrials.gov\/ct2\/show\/NCT01729754"},{"issue":"10091","key":"10.1002\/14651858.CD011535.pub5-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40257-016-0229-x","article-title":"Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab","volume":"17","author":"Armstrong","year":"2016","journal-title":"American Journal of Clinical Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11530640-000000000-00000","article-title":"Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial","volume":"12","author":"Kimball","year":"2011","journal-title":"American Journal of Clinical Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1468-3083.2012.04515.x","article-title":"Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study","volume":"27","author":"Papp","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.13478","article-title":"Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial","volume":"30","author":"Augustin","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archderm.1990.01670280066012","article-title":"Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis","volume":"126","author":"Ruzicka","year":"1990","journal-title":"Archives of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1346-8138.2003.tb00416.x","article-title":"Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from North India","volume":"30","author":"Sandhu","year":"2003","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000248567","article-title":"Randomized double-blind multicenter study comparing acitretin-PUVA, etritinate-PUVA and placebo-PUVA in the treatment of severe psoriasis","volume":"177","author":"Saurat","year":"1988","journal-title":"Dermatologica"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0341|cit341","unstructured":"A study of KHK4827 (brodalumab) in subjects with moderate to severe psoriasis in Korea clinicaltrials.gov\/ct2\/show\/NCT02982005"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/1346-8138.15733","article-title":"Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase III, double-blind, placebo-controlled study","volume":"48","author":"Seo","year":"2021","journal-title":"Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0343|cit343","first-page":"453","article-title":"Efficacy of concomitant use of puva and methotrexate in disease clearance time in plaque type psoriasis","volume":"54","author":"Shehzad","year":"2004","journal-title":"Journal of the Pakistan Medical Association"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0344|cit344","unstructured":"Secukinumab in TNF-IR psoriasis patients (SIGNATURE) clinicaltrials.gov\/ct2\/show\/NCT01961609"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0345|cit345","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjd.18623","article-title":"Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE)","volume":"183","author":"Warren","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"214","DOI":"10.25259\/IJDVL_613_19","article-title":"Safety and efficacy of methotrexate (0.3 mg\/kg\/week) versus a combination of methotrexate (0.15 mg\/kg\/week) with cyclosporine (2.5 mg\/kg\/day) in chronic plaque psoriasis: a randomised non-blinded controlled trial","volume":"87","author":"Singh","year":"2021","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.1993.tb00058.x","article-title":"Acitretin in combination with PUVA: a randomized double-blind placebo-controlled study in severe psoriasis","volume":"2","author":"Sommerburg","year":"1993","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0350|cit350","unstructured":"BI 655066 (risankizumab) compared to placebo in Japanese patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct03000075"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0190-9622(91)70253-X","article-title":"Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study","volume":"25","author":"Tanew","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0353|cit353","unstructured":"A study to assess the efficacy of risankizumab compared to FUMADERM\u00ae in subjects with moderate to severe plaque psoriasis who are naive to and candidates for systemic therapy clinicaltrials.gov\/show\/nct03255382"},{"issue":"186","key":"10.1002\/14651858.CD011535.pub5-BIB0354|cit354","first-page":"30","article-title":"Direct comparison of risankizumab and fumaric acid esters in systemic-therapy-naive patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"15","author":"Thaci","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.17109","article-title":"Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naive patients with moderate to severe plaque psoriasis: a phase 3 clinical trial","volume":"35","author":"Thaci","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0356|cit356","unstructured":"Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-060318"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"Journal of Dermatological Science"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/annrheumdis-2016-eular.5018","article-title":"Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the TRANSFIGURE study","volume":"75","author":"Reich","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2133.2007.08205.x","article-title":"Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks","volume":"157","author":"Krishnan","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1468-3083.2011.04394.x","article-title":"Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept","volume":"27","author":"Tyring","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"9504","key":"10.1002\/14651858.CD011535.pub5-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"S3","key":"10.1002\/14651858.CD011535.pub5-BIB0364|cit364","first-page":"20","article-title":"High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Gooderham","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0365|cit365","first-page":"28","article-title":"Efficacy and safety of risankizumab: results from two double-blind, placebo-and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"10148","key":"10.1002\/14651858.CD011535.pub5-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0367|cit367","unstructured":"BI 655066 compared to placebo & active comparator (Ustekinumab) in patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/ct2\/show\/NCT02684357"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0368|cit368","first-page":"28","article-title":"Efficacy and safety of risankizumab: results from two double-blind, placebo-and ustekinumab-controlled, phase 3 trials in moderate-to-severe plaque psoriasis","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"10148","key":"10.1002\/14651858.CD011535.pub5-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0370|cit370","unstructured":"BI 655066 (Risankizumab) compared to placebo and active comparator (Ustekinumab) in patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/ct2\/show\/NCT02684370"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0371|cit371","unstructured":"A study to test the efficacy and safety of certolizumab pegol in Japanese subjects with moderate to severe chronic psoriasis clinicaltrials.gov\/show\/nct03051217"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13555-021-00494-z","article-title":"Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2\/3 Japanese study","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0374|cit374","first-page":"19","article-title":"Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2\/3 Japanese study","volume":"19","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials","volume":"152","author":"Armstrong","year":"2016","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub5-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"9993","key":"10.1002\/14651858.CD011535.pub5-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"Van de Kerkhof","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000448135","article-title":"Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis: a randomized exploratory study","volume":"232","author":"Van Bezooijen","year":"2016","journal-title":"Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000237871","article-title":"Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis","volume":"219","author":"Reich","year":"2009","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0382|cit382","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"Van de Kerkhof","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo controlled trial of secukinumab on aortic vascular inflammation in moderate to severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0384|cit384","unstructured":"Study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects with moderate to severe plaque psoriasis (VIP-S) clinicaltrials.gov\/ct2\/show\/NCT02690701"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0385|cit385","doi-asserted-by":"publisher","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circulation. Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0386|cit386","unstructured":"Vascular Inflammation in psoriasis trial (the VIP trial) (VIP) clinicaltrials.gov\/ct2\/show\/NCT01553058"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0388|cit388","unstructured":"Vascular inflammation in psoriasis-ustekinumab (VIP-U) clinicaltrials.gov\/show\/nct02187172"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14712598.2021.1851362","article-title":"Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized phase III VOLTAIRE-PSO study","volume":"21","author":"Menter","year":"2021","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"AB5","DOI":"10.1016\/j.jaad.2020.06.108","article-title":"13097 Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks","volume":"83 (6 Suppl)","author":"Menter","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0391|cit391","unstructured":"Efficacy, safety and immunogenicity of BI 695501 versus Humira\u00ae in patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct02850965"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2018","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0394|cit394","first-page":"1580","article-title":"Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 VOYAGE 1 trial","volume":"77","author":"Griffiths","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40257-020-00555-7","article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study","volume":"21","author":"Reich","year":"2020","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0397|cit397","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial","volume":"125","author":"Yang","year":"2012","journal-title":"Chinese Medical Journal"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0398|cit398","first-page":"5068","article-title":"The effects of acitretin on patients with psoriasis vulgaris","volume":"13","author":"Ye","year":"2020","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0399|cit399","first-page":"204","article-title":"Re-PUVA therapy for psoriasis vulgaris: an effective choice","volume":"12","author":"Y\u0131lmaz","year":"2002","journal-title":"T\u00fcrkiye Klinikleri Dermatoloji Dergisi"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011535.pub5-BIB0400|cit400","first-page":"258","article-title":"Re-PUVA therapy for psoriasis vulgaris: an effective choice","volume":"16","author":"Yilmaz","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.intimp.2019.05.042","article-title":"Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis","volume":"73","author":"Yu","year":"2019","journal-title":"International Immunopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0403|cit403","first-page":"S64","article-title":"Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity in psoriasis: early clinical results after single doses","volume":"130","author":"Abufarag","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0404|cit404","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s12325-017-0521-z","article-title":"Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials","volume":"34","author":"Adsit","year":"2017","journal-title":"Advances in Therapy"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1468-3083.2010.03667.x","article-title":"Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis","volume":"24","author":"Akhyani","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0190-9622(94)70121-0","article-title":"Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients","volume":"30","author":"Altmeyer","year":"1994","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8-9","key":"10.1002\/14651858.CD011535.pub5-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-2007-966548","article-title":"Anti-TNF-alpha-therapy of psoriasis with infliximab or etanercept. Clinical, histological and immunohistochemical course","volume":"33","author":"Angsten","year":"2007","journal-title":"Aktuelle Dermatologie"},{"issue":"7-10","key":"10.1002\/14651858.CD011535.pub5-BIB0408|cit408","first-page":"244","article-title":"Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis","volume":"43","year":"2005","journal-title":"Krankenpflege Journal"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0409|cit409","first-page":"880","article-title":"Trial watch: novel biologic for psoriasis shows superiority over current best-seller","volume":"7","year":"2008","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0410|cit410","first-page":"AB60","article-title":"Evaluation of effectiveness and safety in two optimization strategies with secukinumab in the treatment of moderate severe psoriasis","volume":"81 (4 Suppl 1)","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0411|cit411","first-page":"142","article-title":"Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis-results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"76","author":"Araujo","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/S0926-9959(98)95686-0","article-title":"Acitretin (neotigason) in the treatment of psoriasis","volume":"11","author":"Arifov","year":"1998","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1440-0960.1972.tb00490.x","article-title":"Retinoic acid for psoriasis","volume":"13","author":"Armati","year":"1972","journal-title":"Australasian Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0416|cit416","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/jdv.13823","article-title":"Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis","volume":"31","author":"Augustin","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijcard.2011.06.112","article-title":"Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis","volume":"151","author":"Avgerinou","year":"2011","journal-title":"International Journal of Cardiology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0418|cit418","first-page":"613","article-title":"Effect of tofacitinib on efficacy and patient-reported outcomes in psoriasis patients with baseline psoriatic arthritis: a pooled analysis of 2 phase 3 studies","volume":"69","author":"Bachelez","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0419|cit419","first-page":"S14","article-title":"Ease of use and confidence using auto-injector to administer ixekizumab in a phase 3 trial evaluated with subcutaneous administration assessment questionnaire (SQAAQ)","volume":"10","author":"Bagel","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0420|cit420","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjd.15381","article-title":"Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab","volume":"177","author":"Bagel","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0422|cit422","first-page":"1078","article-title":"Open-label study to evaluate the efficacy of etanercept treatment in subjects with moderate to severe plaque psoriasis who have failed therapy with apremilast","volume":"17","author":"Bagel","year":"2018","journal-title":"Journal of Drugs in Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"e12467","DOI":"10.1111\/dth.12467","article-title":"Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis","volume":"30","author":"Bagherani","year":"2017","journal-title":"Dermatologic Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0424|cit424","first-page":"282","article-title":"Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis","volume":"317","author":"Bagot","year":"1994","journal-title":"Comptes Rendus de l'Acad\u00e9mie des Sciences. S\u00e9rie III, Sciences de la Vie"},{"issue":"9625","key":"10.1002\/14651858.CD011535.pub5-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(08)60702-3","article-title":"Ustekinumab for chronic plaque psoriasis","volume":"371","author":"Bartlett","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0426|cit426","first-page":"31","article-title":"Comparison of bath PUVA and acitretin in treatment of psoriatic patients","volume":"7","author":"Barzegari","year":"2004","journal-title":"Iranian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archdermatol.2009.104","article-title":"Adalimumab vs methotrexate for the treatment of chronic plaque psoriasis","volume":"145","author":"Batchelor","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"1-2","key":"10.1002\/14651858.CD011535.pub5-BIB0428|cit428","first-page":"27","article-title":"Treatment of psoriasis vulgaris with etretinate versus cyclosporin A. Report on a study","volume":"18","author":"Bayerl","year":"1992","journal-title":"Aktuelle Dermatologie"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000226134","article-title":"A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis","volume":"219","author":"Beissert","year":"2009","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000248398","article-title":"Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis","volume":"178","author":"Berbis","year":"1989","journal-title":"Dermatologica"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0431|cit431","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/2229-5178.198765","article-title":"Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study","volume":"8","author":"Bhat","year":"2017","journal-title":"Indian Dermatology Online Journal"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0432|cit432","first-page":"146","article-title":"Role of oral colchicine in plaque type psoriasis. A randomized clinical trial comparing with oral methotrexate","volume":"20","author":"Bhuiyan","year":"2010","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0433|cit433","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab treatment in moderate-to-severe psoriasis patients demonstrates sustained low absolute PASI up to 4 years: results from SCULPTURE extension study","volume":"59","author":"Bian","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0434|cit434","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archderm.140.3.347","article-title":"A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis","volume":"140","author":"Bigby","year":"2004","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2005.10.061","article-title":"A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis","volume":"54","author":"Bissonnette","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2009.05.042","article-title":"A randomized, double-blind, placebo-controlled, phase I study of medi-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis","volume":"62","author":"Bissonnette","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0438|cit438","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0439|cit439","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-\u03b1 antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0440|cit440","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jdv.14647","article-title":"Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study","volume":"32","author":"Bissonnette","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0441|cit441","first-page":"206","article-title":"Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients","volume":"146","author":"Bjerke","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"issue":"S4","key":"10.1002\/14651858.CD011535.pub5-BIB0442|cit442","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/exd.13200","article-title":"Efficacy and safety of ixekizumab in patients previously treated with etanercept","volume":"25","author":"Blauvelt","year":"2016","journal-title":"Experimental Dermatology"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.jid.2016.06.408","article-title":"Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis","volume":"136","author":"Blauvelt","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0444|cit444","first-page":"e249","article-title":"Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of three randomized controlled trials","volume":"177","author":"Blauvelt","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.14309\/00000434-201710001-00751","article-title":"Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab","volume":"112","author":"Blauvelt","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","volume":"177","author":"Blauvelt","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaad.2017.03.026","article-title":"Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0449|cit449","first-page":"S15","article-title":"Efficacy and safety of continuous ixekizumab treatment for 60 weeks in moderate-to-severe plaque psoriasis: results from the UNCOVER-3 trial","volume":"10","author":"Blauvelt","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0450|cit450","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-016-0246-9","article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3)","volume":"18","author":"Blauvelt","year":"2017","journal-title":"American Journal of Clinical Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0451|cit451","first-page":"1264","article-title":"Secukinumab retreatment shows rapid recapture of treatment response: an analysis of a phase 3 extension trial in psoriasis","volume":"56","author":"Blauvelt","year":"2017","journal-title":"International Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0453|cit453","first-page":"S22","article-title":"Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210mg or ustekinumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)","volume":"10","author":"Blauvelt","year":"2017","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0454|cit454","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jid.2017.07.593","article-title":"Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: results through 108 weeks randomised, phase III clinical trial (UNCOVER-3)","volume":"137","author":"Blauvelt","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0455|cit455","first-page":"22","article-title":"Predictors of response to tildrakizumab for moderate to severe chronic plaque psoriasis","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0456|cit456","first-page":"49","article-title":"Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0457|cit457","first-page":"21","article-title":"Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through week 24 from the phase 3, double-blinded, placebo-and active comparator-controlled voyage 1 and voyage 2 trials","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0458|cit458","first-page":"21","article-title":"Safety of certolizumab pegol over 48 weeks in chronic plaque psoriasis phase 3 trials","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0459|cit459","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jdv.15258","article-title":"Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials","volume":"33","author":"Blauvelt","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/09546634.2017.1365114","article-title":"Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab","volume":"29","author":"Blauvelt","year":"2018","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0462|cit462","first-page":"31","article-title":"Better skin clearance is associated with improved quality of life in moderate-to-severe psoriasis patients treated with tildrakizumab","volume":"98","author":"Blauvelt","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaad.2020.06.152","article-title":"14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2)","volume":"83 6 Suppl","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/j.jid.2017.07.103","article-title":"Sustained response following withdrawal of guselkumab treatment correlates with reduced Th17 and Th22 effector cytokine levels","volume":"137","author":"Branigan","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0466|cit466","unstructured":"Medicamentos biol\u00f3gicos (infliximabe, etanercepte, adalimumabe e ustequinumabe) para o tratamento da psor\u00edase moderada a grave em adultos conitec.gov.br\/images\/Incorporados\/Biologicos-Psoriase-final.pdf"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0467|cit467","unstructured":"Golimumabe para artrite psori\u00e1sica conitec.gov.br\/images\/Incorporados\/Golimumabe-ArtritePsoriasica-final.pdf"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0468|cit468","unstructured":"Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS Golimumabe para o tratamento da artrite psori\u00e1sica conitec.gov.br\/images\/Relatorios\/2016\/Relatorio_Golimumabe_ArtritePsoriasica_final.pdf"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0469|cit469","first-page":"18","article-title":"Efficacy and tolerability about ustekinumab in patients withpsoriatic arthritis after 24 months of treatment","volume":"14 (Suppl 2)","author":"Buono","year":"2020","journal-title":"Italian Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0470|cit470","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjd.15160","article-title":"Etanercept or infliximab for psoriasis? An independent randomized clinical trial","volume":"176","author":"Burden","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0471|cit471","first-page":"42","article-title":"Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): descriptive analysis in patients with moderate-to-severe plaque psoriasis","volume":"58","author":"Burkhardt","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jdv.13768","article-title":"Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)","volume":"31","author":"Callis Duffin","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/205873920601900123","article-title":"Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study)","volume":"19","author":"Cassano","year":"2006","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/039463201002300314","article-title":"Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group","volume":"23","author":"Cassano","year":"2010","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0475|cit475","first-page":"AB217 (abstract","article-title":"Efficacy and safety of low-dose acitretin for the treatment of moderate to severe plaque-type psoriasis","volume":"54","author":"Cather","year":"2006","journal-title":"Journal of the American Academy of Dermatology (American Academy of Dermatology 64th Annual Meeting March 3-7, 2006)"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0476|cit476","first-page":"11","article-title":"Ixekizumab improves impact of genital psoriasis on sexual activity: results from a phase 3b study","volume":"98","author":"Cather","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0477|cit477","first-page":"e291","article-title":"One-year pilot study to evaluate sequential therapy with ciclosporin and itolizumab in treatment of chronic plaque psoriasis","volume":"177","author":"Chakravadhanula","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0478|cit478","first-page":"46","article-title":"Sustained improvement in patient-reported outcomes with continued apremilast treatment over 104 weeks in patients with moderate to severe psoriasis","volume":"59","author":"Chapman","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0479|cit479","unstructured":"A comparative study to evaluate the pharmacokinetics and safety of BAT2206 injection vs ustekinumab injection (stelara) in healthy Chinese male subjects www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000030273"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0480|cit480","unstructured":"Acitretin plus methotrexate in the treatment of moderate to severe psoriasis vulgaris www.chictr.org.cn\/showprojen.aspx?proj=16444\/ChiCTR-INR-16009710"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.2002.01621.x","article-title":"Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis","volume":"54","author":"Chl\u00e1dek","year":"2002","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0482|cit482","first-page":"173","article-title":"Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods","volume":"54","author":"Chodorowska","year":"1999","journal-title":"Annales Universitatis Mariae Curie-Sklodowska. Section D: Medicina"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0483|cit483","first-page":"S330","article-title":"Plasma levels of selected cytokines and acute phase proteins in 2 groups of psoriatic patients treated with cyclosporine A or RE-PUVA method","volume":"12","author":"Chodorowska","year":"1999","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/bjd.15350","article-title":"The objective Psoriasis Area and Severity Index: a randomized controlled pilot study comparing the effectiveness of ciclosporin and methotrexate","volume":"177","author":"Choi","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0485|cit485","first-page":"25","article-title":"Long-term safety and efficacy of adalimumab from the phase 3 randomized, placebo-controlled trial in patients with nail and skin psoriasis","volume":"98","author":"Crowley","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0486|cit486","first-page":"29","article-title":"Efficacy of tildrakizumab in etanercept partial responders or nonresponders","volume":"98","author":"Crowley","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0487|cit487","unstructured":"Comparison of efficacy and safety of oral vs subcutaneous methotrexate in psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2018\/01\/011373"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0488|cit488","unstructured":"A comparative study for the efficacy and side effects in subcutaneous and oral methotrexate in patients of chronic plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/07\/026598"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0489|cit489","unstructured":"Fasting in managment of psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/12\/029472"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0490|cit490","unstructured":"A study to check effectiveness of dimethyl fumarate gastro-resistant hard capsule in patients with moderate to severe chronic plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/12\/029611"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1365-2133.2003.05173.x","article-title":"The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial","volume":"148","author":"De Jong","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0492|cit492","first-page":"S102","article-title":"A longitudinal PKPD model describing the effect of ixekizumab on static physician's global assessment score (sPGA) in patients with moderate-to-severe plaque psoriasis","volume":"44","author":"De Mendizabal","year":"2017","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"13","key":"10.1002\/14651858.CD011535.pub5-BIB0493|cit493","first-page":"545","article-title":"Experimental treatment with fumaric acid monoethylester in psoriasis vulgaris","volume":"47","author":"Dubiel","year":"1972","journal-title":"Zeitschrift fur Haut- und Geschlechtskrankheiten"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0494|cit494","first-page":"AB242","article-title":"Comparison of the pharmacokinetics of ixekizumab following subcutaneous administration using a prefilled syringe versus an autoinjector in patients with moderate-to-severe psoriasis","volume":"74","author":"Duffin","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0495|cit495","first-page":"147","article-title":"Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2","volume":"16","author":"Duffin","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0496|cit496","first-page":"97","article-title":"Psoriasis vulgaris: How effective and safe is the calcineurin inhibitor voclosporin?","volume":"27","author":"Ecker-Schlipf","year":"2009","journal-title":"Arzneimitteltherapie"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0497|cit497","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jdv.12186","article-title":"A PASI \u2265 90 response is associated with improved patient reported outcomes: results from a phase 2 study in patients with psoriasis treated with ixekizumab","volume":"27","author":"Edson-Heredia","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"21","key":"10.1002\/14651858.CD011535.pub5-BIB0498|cit498","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc1610828","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Egeberg","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2133.2006.07585.x","article-title":"Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis","volume":"156","author":"Elewski","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab","volume":"28","author":"Elewski","year":"2017","journal-title":"Journal of Dermatological Treatment"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0501|cit501","first-page":"S25","article-title":"Sustained and improved efficacy of tildrakizumab from week 28 to week 52 in treating moderate-to-severe plaque psoriasis","volume":"11","author":"Elewski","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0502|cit502","first-page":"31","article-title":"Sustained and improved efficacy of tildrakizumab from week 28 to week 52 in treating moderate-to-severe plaque psoriasis","volume":"98","author":"Elewski","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"22","key":"10.1002\/14651858.CD011535.pub5-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00128071-200304020-00005","article-title":"Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial","volume":"4","author":"Ellis","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0506|cit506","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mjd.2002.119196","article-title":"Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate","volume":"46","author":"Ellis","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0507|cit507","first-page":"S81","article-title":"Evaluation of Psoriasis Area and Severity Index, Static Physician's Global Assessment, and Lattice System - Physician's Global Assessment for assessing severity of psoriasis","volume":"131","author":"Chow","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0508|cit508","first-page":"486","article-title":"Results of cyclosporin treatment of severe, chronical psoriasis vulgaris","volume":"40","author":"Engst","year":"1989","journal-title":"Hautarzt"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0509|cit509","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1046\/j.1365-2133.1997.d01-1147.x","article-title":"Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis","volume":"136","author":"Erkko","year":"1997","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0510|cit510","unstructured":"A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-004328-18-FR"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0511|cit511","unstructured":"A study to compare the efficacy of a new developed product, FP187, to a marketed product, to each other but also to placebo, in patients with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-005685-35-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0512|cit512","unstructured":"Study to evaluate the efficacy and safety of high induction doses of adalimumab in moderate to severe psoriasis patients www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-001593-15-ES"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0513|cit513","unstructured":"Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-003592-21-GB"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0514|cit514","unstructured":"A clinical study with brodalumab for patients suffering from psoriasis and not benefitting the TNF-alpha treatment www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-001021-10-SE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0515|cit515","unstructured":"An open-label, randomized, phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-000817-35-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0516|cit516","unstructured":"Efficacy and safety of tildrakizumab in participants with moderate-to-severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy (TRANSITION) clinicaltrials.gov\/show\/NCT04263610"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0517|cit517","unstructured":"Gottlieb AB Merola JF Reich K Behrens F Nash P Griffiths CEM Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: results from the EXCEED, a randomised, double-blind head-to-head monotherapy study British Journal of Dermatology 10.1111\/bjd.20413"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0518|cit518","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2340\/00015555-0290","article-title":"Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis","volume":"87","author":"Ezquerra","year":"2007","journal-title":"Acta Dermato-Venereologica"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0519|cit519","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/09546634.2017.1329502","article-title":"Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis","volume":"28","author":"Feldman","year":"2017","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaad.2012.08.013","article-title":"Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy","volume":"68","author":"Fernandes","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0521|cit521","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jid.2017.02.354","article-title":"Long-term clinical outcomes after 2 years of ixekizumab treatment in patients with moderate-to-severe psoriasis with a focus on absolute PASI","volume":"137","author":"Fernandez Penas","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000247286","article-title":"Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis","volume":"187","author":"Italian Multicenter Study Group on Cyclosporin in Psoriasis","year":"1993","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0523|cit523","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ced.13561","article-title":"Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis","volume":"43","author":"Fitz","year":"2018","journal-title":"Clinical and Experimental Dermatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0524|cit524","first-page":"A46","article-title":"A randomized, double-blind, right\/left comparative study of the efficacy of acitretin with and without the co-administration of 0.1 percent tacrolimus ointment in the treatment of moderate to severe psoriasis","volume":"124","author":"Fleischer","year":"2005","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0525|cit525","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1111\/bjd.16059","article-title":"Guselkumab treatment provided higher frequency of complete skin clearance compared with adalimumab treatment among patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Foley","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0527|cit527","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000252380","article-title":"Antipsoriatic activity of retinoic acid (vitamin A acid)","volume":"142","author":"Fredriksson","year":"1971","journal-title":"Dermatologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis - oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0529|cit529","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/000155501317208408","article-title":"Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis","volume":"81","author":"Friedrich","year":"2001","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjd.19398","article-title":"Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study","volume":"184","author":"Reich","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1365-2133.2011.10358.x","article-title":"Etanercept plus narrowband ultraviolet b phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks","volume":"164","author":"Gambichler","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0532|cit532","first-page":"807","article-title":"Etanercept therapy provides clinically meaningful improvement in dermatology quality of life index in patients with chronic plaque psoriasis","volume":"18","author":"Ganguly","year":"2004","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub5-BIB0533|cit533","first-page":"383","article-title":"Association between calcitriol per os and acitretinoin in the treatment of psoriasis","volume":"17","author":"Gil","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"e14281","DOI":"10.1111\/dth.14281","article-title":"Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome","volume":"33","author":"Gisondi","year":"2020","journal-title":"Dermatologic Therapy"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0535|cit535","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000250883","article-title":"Systemic treatment of psoriasis with a new aromatic retinoid. Preliminary evaluation of a multicenter controlled study in the Federal Republic of Germany","volume":"157","author":"Goerz","year":"1978","journal-title":"Dermatologica"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0537|cit537","first-page":"S23","article-title":"Impact on quality of life and satisfaction with apremilast in patients with moderate plaque psoriasis: 52-week results of the UNVEIL study","volume":"11","author":"Gold","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0538|cit538","first-page":"2800","article-title":"Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a randomized Norwegian trial","volume":"69","author":"Goll","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0539|cit539","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1136\/annrheumdis-2018-eular.4620","article-title":"Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a Norwegian randomised trial","volume":"77","author":"Goll","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(88)70198-X","article-title":"Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study","volume":"19","author":"Gollnick","year":"1988","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0541|cit541","first-page":"442","article-title":"Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study","volume":"3","author":"Gollnick","year":"1993","journal-title":"European Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0542|cit542","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000063148","article-title":"Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris","volume":"205","author":"Gollnick","year":"2002","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0543|cit543","first-page":"AB183","article-title":"Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis","volume":"70","author":"Gordon","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0544|cit544","first-page":"S17","article-title":"Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis","volume":"8","author":"Gordon","year":"2015","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0545|cit545","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2340\/00015555-2978","article-title":"Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: results from voyage 2","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0546|cit546","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2340\/00015555-2978","article-title":"Efficacy of tildrakizumab in moderate to severe psoriasis patients with prior exposure to apremilast","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0547|cit547","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2340\/00015555-2978","article-title":"Disease severity and efficacy insights: patient-level pasi scores in tildrakizumab psoriasis trials","volume":"98","author":"Gordon","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase 3 VOYAGE 2 study","volume":"32","author":"Gordon","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0549|cit549","first-page":"1098","article-title":"Alefacept (AMEVIVETM) does not blunt primary or secondary immune responses","volume":"118","author":"Gottlieb","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0550|cit550","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0190-9622(03)01836-X","article-title":"CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study","volume":"49","author":"Gottlieb","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0551|cit551","first-page":"68","article-title":"Prolonged response durability following ENBRELA\u00ae (etanercept) monotherapy","volume":"121","author":"Gottlieb","year":"2003","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0552|cit552","first-page":"A55","article-title":"Safety of etanercept in an integrated multistudy database of patients with psoriasis","volume":"122","author":"Gottlieb","year":"2004","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2133.2005.06661.x","article-title":"Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial","volume":"152","author":"Gottlieb","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0554|cit554","first-page":"AB8","article-title":"A phase II trial of a new anti-inflammatory combination drug, CRx-140, in subjects with severe psoriasis","volume":"54","author":"Gottlieb","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0555|cit555","first-page":"AB10","article-title":"Preliminary clinical safety and efficacy results from an open-label phase 2 study of STA-5326, an oral IL-12\/IL-23 inhibitor, in patients with moderate to severe chronic plaque psoriasis","volume":"54","author":"Gottlieb","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9664","key":"10.1002\/14651858.CD011535.pub5-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.jid.2016.06.069","article-title":"Efficacy of ixekizumab in moderate-to-severe psoriasis patients who have or have not received prior biologic therapies: an integrated analysis of 3 phase 3 studies","volume":"136","author":"Gottlieb","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0558|cit558","first-page":"e261","article-title":"Secukinumab shows high and sustained efficacy in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from the GESTURE study","volume":"177","author":"Gottlieb","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial","volume":"76","author":"Gottlieb","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaad.2017.06.162","article-title":"Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and Body Surface Area (PGA x BSA) composite tool: an analysis of apremilast phase 3 ESTEEM data","volume":"77","author":"Gottlieb","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jdv.13990","article-title":"Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies","volume":"31","author":"Gottlieb","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jdv.14913","article-title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","volume":"32","author":"Gottlieb","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0563|cit563","first-page":"24","article-title":"Durable reduction in absolute pasi with certolizumab pegol in patients with chronic plaque psoriasis","volume":"98","author":"Gottlieb","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0564|cit564","first-page":"2369","article-title":"Is methotrexate really effective in patients with psoriatic arthritis?","volume":"22","author":"Goupille","year":"1995","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0565|cit565","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/annrheumdis-2018-eular.2132","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"77","author":"Goupille","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD011535.pub5-BIB0566|cit566","first-page":"19","article-title":"A double-blind, randomised trial to compare the effects of oral liarozole with acitretin in the treatment of chronic plaque psoriasis","volume":"139","author":"Griffiths","year":"1998","journal-title":"British Journal of Dermatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011535.pub5-BIB0567|cit567","first-page":"292","article-title":"Relationship between clinical response and quality of life in psoriasis patients treated with alefacept","volume":"16","author":"Griffiths","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 62","key":"10.1002\/14651858.CD011535.pub5-BIB0568|cit568","first-page":"45","article-title":"Effect of alefacept based on patients' response to prior therapy for psoriasis","volume":"147","author":"Griffiths","year":"2002","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0569|cit569","first-page":"7","article-title":"A higher treatment standard for patients with moderate to severe psoriasis","volume":"19","author":"Griffiths","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0570|cit570","doi-asserted-by":"publisher","first-page":"AB137","DOI":"10.1016\/j.jaad.2009.11.527","article-title":"Ustekinumab treatment in patients with moderate to severe psoriasis who are nonresponders to etanercept: results from a phase III clinical trial","volume":"62","author":"Griffiths","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011535.pub5-BIB0571|cit571","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.14524","article-title":"Efficacy and safety of ixekizumab in patients with psoriasis who failed initial etanercept treatment: a subanalysis from UNCOVER 2, a randomized, double-blind, multicentre, phase III clinical trial","volume":"175","author":"Griffiths","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0572|cit572","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/jdv.13808","article-title":"Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a phase 3 study in patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Griffiths","year":"2017","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0573|cit573","first-page":"826","article-title":"Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years","volume":"17","author":"Griffiths","year":"2018","journal-title":"Journal of Drugs in Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0574|cit574","first-page":"20","article-title":"Clinical response after guselkumab treatment among adalimumab PASI 90 non-responders: results from the Voyage 1 and 2 trials","volume":"98","author":"Griffith","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0575|cit575","first-page":"46","article-title":"Secukinumab's long-term safety remains favorable up to 5 years of treatment","volume":"98","author":"Griffiths","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0576|cit576","first-page":"390","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of low dose methotrexate (LDMTX) in the treatment of psoriasis","volume":"50","author":"Grim","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0190-9622(94)70138-5","article-title":"A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study","volume":"31","author":"Grossman","year":"1994","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0578|cit578","doi-asserted-by":"crossref","first-page":"adv00006","DOI":"10.2340\/00015555-3353","article-title":"Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week randomized, placebo-controlled, phase 3 clinical trial","volume":"100","author":"Guenther","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"issue":"s48","key":"10.1002\/14651858.CD011535.pub5-BIB0579|cit579","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2133.1996.tb00708.x","article-title":"Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin","volume":"135","author":"Gulliver","year":"1996","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0580|cit580","first-page":"247","article-title":"Comparative efficacy of methotrexate and hydroxyurea in treatment of psoriasis","volume":"15","author":"Gupta","year":"2005","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0581|cit581","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09546630701487643","article-title":"Methotrexate-betamethasone weekly oral pulse in psoriasis","volume":"18","author":"Gupta","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0582|cit582","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2310\/7750.2008.07060","article-title":"ISA247: quality of life results from a phase II, randomized, placebo-controlled study","volume":"12","author":"Gupta","year":"2008","journal-title":"Journal of Cutaneous Medicine and Surgery"},{"issue":"S10","key":"10.1002\/14651858.CD011535.pub5-BIB0583|cit583","first-page":"S137","article-title":"Sustained improvement in health-related quality of life, work productivity, employability, and reduced healthcare resource utilization of patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with golimumab: 5-year results from 3 phase III studies","volume":"65","author":"Han","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0584|cit584","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1346-8138.2007.00305.x","article-title":"Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris","volume":"34","author":"Hashizume","year":"2007","journal-title":"Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0585|cit585","first-page":"S28","article-title":"Secukinumab for the treatment of scalp, nail, and palmoplantar psoriasis","volume":"11","author":"Hawkes","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3 Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0586|cit586","first-page":"32","article-title":"Low-dose cyclosporine effective in severe psoriasis: a double-blind study","volume":"20","author":"Heule","year":"1988","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2009.03693.x","article-title":"Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life","volume":"35","author":"Ho","year":"2010","journal-title":"Clinical and Experimental Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.16635","article-title":"Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial","volume":"35","author":"Holzer","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0589|cit589","first-page":"S27","article-title":"Efficacy of brodalumab in ustekinumab-naive and-experienced patients with moderate-to-severe plaque psoriasis","volume":"11","author":"Hsu","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0590|cit590","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1440-0960.1972.tb00495.x","article-title":"A clinical trial of hydroxyurea for psoriasis","volume":"13","author":"Hunter","year":"1972","journal-title":"Australasian Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2133.1989.tb01354.x","article-title":"Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone","volume":"120","author":"Iest","year":"1989","journal-title":"British Journal of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1346-8138.13927","article-title":"Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)","volume":"44","author":"Imafuku","year":"2017","journal-title":"Journal of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.14979","article-title":"Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study","volume":"32","author":"Iversen","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0594|cit594","first-page":"S20","article-title":"Improvement in scalp and nails with apremilast in patients with moderate plaque psoriasis naive to systemic and biologic therapy: 52-week results of the UNVEIL study","volume":"11","author":"Jackson","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/archderm.144.8.1067","article-title":"The role of narrowband UV-B plus alefacept combination therapy in the treatment of psoriasis","volume":"144","author":"Jacobe","year":"2008","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0596|cit596","unstructured":"A multicenter, randomized, open-label study to evaluate the safe and effective use of the prefilled safety syringe or the auto-injector for the subcutaneous self-injection of bimekizumab solution by subjects with moderate to severe chronic plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-194706"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/ds.ds_22_19","article-title":"Efficacy of tofacitinib in patients with moderate-to-severe psoriasis who had inadequate responses to prior biologics","volume":"37","author":"Huang","year":"2019","journal-title":"Dermatologica Sinica"},{"issue":"2-3","key":"10.1002\/14651858.CD011535.pub5-BIB0598|cit598","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475809","article-title":"Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients","volume":"233","author":"Jin","year":"2017","journal-title":"Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0599|cit599","unstructured":"Comparison of phototherapy alone or together with apremilast in psoriasis vulgaris patients www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-jRCTs041180012"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0600|cit600","article-title":"A placebo-controlled, randomized trial to assess, using pet scan, systemic and vascular inflammation, and response to therapy, in patients with psoriasis","volume":"12","author":"Kaur","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association (Conference: 24th World Congress of Dermatology, Italy)"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0601|cit601","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4103\/ijdvl.IJDVL_717_17","article-title":"18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: a randomized placebo-controlled pilot study","volume":"84","author":"Kaur","year":"2018","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-009-0043-z","article-title":"The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis","volume":"11","author":"Kavanaugh","year":"2009","journal-title":"Current Rheumatology Reports"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2018.1473551","article-title":"Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3","volume":"30","author":"Kemeny","year":"2019","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0605|cit605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.01.030","article-title":"Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12\/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation\/retreatment and 60-week open-label extension phases of a randomized phase II trial","volume":"64","author":"Kimball","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2340\/00015555-2801","article-title":"Long-term impact of ixekizumab on psoriasis itch severity: results from a phase III clinical trial and long-term extension","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0607|cit607","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1365-2133.1998.02319.x","article-title":"A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis","volume":"139","author":"Koo","year":"1998","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0608|cit608","doi-asserted-by":"crossref","unstructured":"Kopp T Riedl E Bangert C Bowman EP Greisenegger E Horowitz A Clinical improvement in psoriasis with specific targeting of interleukin-23 Nature 2015 521 7551 222 6","DOI":"10.1038\/nature14175"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0609|cit609","first-page":"47","article-title":"Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8\/patera study","volume":"59","author":"Korotaeva","year":"2021","journal-title":"Nauchno-Prakticheskaya Revmatologiya"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0610|cit610","first-page":"35","article-title":"A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study","volume":"69","author":"Kragballe","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0611|cit611","unstructured":"Krishnan KR Cella D Woolley M Lalla D Zitnik R Brajac D Etanercept improves symptoms of depression and fatigue in patients with psoriasis 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, GA 2005 NR293"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0612|cit612","first-page":"A451","article-title":"Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: results from two double-blind randomized controlled studies","volume":"6","author":"Krishnan","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0613|cit613","first-page":"937","article-title":"Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior TNF inadequate response","volume":"76","author":"Kristensen","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0614|cit614","first-page":"21A","article-title":"Comparison of labelling indices of skin involved and uninvolved with psoriasis: placebo and oral retinoid RO 10-9359 vs. time","volume":"28","author":"Krueger","year":"1980","journal-title":"Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2133.2004.05697.x","article-title":"Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis","volume":"150","author":"Feldman","year":"2004","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","article-title":"A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis","volume":"47","author":"Krueger","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1468-3083.17.s2.4.x","article-title":"Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plague psoriasis","volume":"17","author":"Krueger","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaad.2005.10.006","article-title":"The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis","volume":"54","author":"Menter","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0619|cit619","first-page":"1098","article-title":"Pharmacodynamic effects of IM or IV alefacept: selective reductions in memory- effector (CD45RO+) cells are related to clinical improvement in psoriasis","volume":"118","author":"Krueger","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0620|cit620","first-page":"57","article-title":"Repeated courses of IM alefacept in psoriasis: rationale and design of an international study that mimics the clinical practice setting","volume":"121","author":"Krueger","year":"2003","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0624|cit624","first-page":"26","article-title":"Secukinumab, a new anti-IL17A biologic therapy, induces rapid and durable clinical, histological, and molecular resolution of psoriasis plaques over 1 year of administration","volume":"25","author":"Krueger","year":"2016","journal-title":"Experimental Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2015.03.040","article-title":"Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: a double-blind, randomized-withdrawal, placebo-controlled study","volume":"73","author":"Dogra","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2014.01.897","article-title":"Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study","volume":"71","author":"Krupashankar","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2133.1998.02399.x","article-title":"The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin","volume":"139","author":"Kuijpers","year":"1998","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ijd.12585","article-title":"The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial","volume":"54","author":"Lajevardi","year":"2015","journal-title":"International Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0629|cit629","first-page":"36","article-title":"Clinical signs of epithelial surface disruption impact pain and sexual health in patients with moderate-to-severe genital psoriasis","volume":"179","author":"Lambert","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0630|cit630","first-page":"240","article-title":"The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis","volume":"19","author":"Langewouters","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0631|cit631","unstructured":"Langley R Leondardi C Okun M Long-term safety and efficacy of adalimumab in psoriasis 4th European Association of Dermatology and Venereology (EADV) Spring Symposium Saariselka, Lapland, Finland. February 9-12th, 2006 2006 P 021"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0632|cit632","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-4632.2010.04512.x","article-title":"Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies","volume":"49","author":"Langley","year":"2010","journal-title":"International Journal of Dermatology"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0633|cit633","first-page":"S169","article-title":"Treatment with ixekizumab over 60 weeks provides sustained improvements in healthrelated quality of life: results from UNCOVER-1, a randomized phase 3 trial","volume":"136","author":"Langley","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0634|cit634","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0635|cit635","first-page":"798","article-title":"Results of a phase II study of a novel oral fumarate, BG-12, in the treatment of severe psoriasis","volume":"18","author":"Langner","year":"2004","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2133.1989.tb01406.x","article-title":"A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis","volume":"121","author":"Lauharanta","year":"1989","journal-title":"British Journal of Dermatology"},{"issue":"8326 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(83)91994-3","article-title":"Addition of retinoids to PUVA for psoriasis","volume":"1","author":"Lawrence","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archderm.1970.04000080016003","article-title":"Hydroxyurea. A new treatment for psoriasis","volume":"102","author":"Leavell","year":"1970","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000069942","article-title":"Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis","volume":"206","author":"Finlay","year":"2003","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0641|cit641","first-page":"117","article-title":"Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis","volume":"13","author":"Ortonne","year":"2003","journal-title":"European Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1468-3083.17.s2.3.x","article-title":"Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patient with chronic plaque psoriasis","volume":"17","author":"Ortonne","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub5-BIB0643|cit643","first-page":"377","article-title":"The effect of psoriasis and its treatments on circulating T-cell subsets: results of alefacept studies","volume":"17","author":"Lebwohl","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0644|cit644","first-page":"AB167","article-title":"Comparable efficacy and safety of ustekinumab in moderate to severe psoriasis patients previously treated with systemic therapies and treatment-naive patients","volume":"60","author":"Lebwohl","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0645|cit645","first-page":"S39","article-title":"Safety and efficacy of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis","volume":"2","author":"Lebwohl","year":"2012","journal-title":"Dermatology and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0646|cit646","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2013.03.031","article-title":"A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis","volume":"69","author":"Lebwohl","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-4362.1988.tb02429.x","article-title":"Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate","volume":"27","author":"Ledo","year":"1988","journal-title":"International Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0648|cit648","first-page":"A4","article-title":"Alefacept plus 311 nm narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of psoriasis","volume":"125","author":"Legat","year":"2005","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0649|cit649","first-page":"22","article-title":"Characterization of infections associated with ustekinumab in moderate to severe psoriasis patients","volume":"24","author":"Leonardi","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0650|cit650","first-page":"9","article-title":"Efficacy and safety of weekly adalimumab in psoriasis patients with a less than PASI 50 response to 40 mg every other week: results from an open-label extension study","volume":"24","author":"Leonardi","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0651|cit651","first-page":"26","article-title":"Long-term safety of adalimumab for psoriasis: an analysis of all adalimumab exposure in all global clinical trials","volume":"24","author":"Leonardi","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0652|cit652","doi-asserted-by":"publisher","first-page":"AB149","DOI":"10.1016\/j.jaad.2010.09.608","article-title":"Sustained improvement in skin disease specific quality of life in patients with moderate to severe psoriasis receiving ustekinumab maintenance therapy: long-term results from PHOENIX 1","volume":"64","author":"Leonardi","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0653|cit653","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0654|cit654","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2340\/00015555756569","article-title":"Remission of ordinary psoriasis following a short clearance course of cyclosporin","volume":"75","author":"Levell","year":"1995","journal-title":"Acta Dermato-Venereologica"},{"issue":"10 A","key":"10.1002\/14651858.CD011535.pub5-BIB0655|cit655","first-page":"S81","article-title":"Work\/study productivity gain and indirect cost savings with guselkumab compared with adalimumab in moderate to severe psoriasis: results from the VOYAGE 1 study","volume":"24","author":"Li","year":"2018","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0656|cit656","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/09546639509097154","article-title":"Combination therapy and the use of an initial dose of intramuscular methotrexate in patients hospitalized for psoriasis","volume":"6","author":"Liang","year":"1995","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0657|cit657","first-page":"2492","article-title":"The long-term safety and durability of response of CHS-0214, a proposed biosimilar to etanercept: an open-label safety extension study","volume":"69","author":"Louw","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0658|cit658","first-page":"AB150","article-title":"Efficacy and safety of alefacept in combination with narrowband UVB compared to alefacept alone in subjects with moderate to severe psoriasis: results of the Canadian alefacept phototherapy psoriasis study","volume":"64","author":"Lui","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0659|cit659","first-page":"929","article-title":"A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response","volume":"11","author":"Lui","year":"2012","journal-title":"Journal of Drugs in Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0660|cit660","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/09546634.2011.607795","article-title":"A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept","volume":"23","author":"Lynde","year":"2012","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0661|cit661","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2133.1972.tb16108.x","article-title":"Retinoic acid in the treatment of psoriasis","volume":"86","author":"Macdonald","year":"1972","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0662|cit662","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0190-9622(95)90189-2","article-title":"Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement","volume":"32","author":"Mahrle","year":"1995","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0663|cit663","first-page":"152","article-title":"Comparison of methotrexate and azathioprine in the treatment of psoriasis: a randomized controlled trial","volume":"20","author":"Malik","year":"2010","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0664|cit664","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1420","article-title":"Efalizumab","volume":"3","author":"Marecki","year":"2004","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0665|cit665","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2133.1986.tb06663.x","article-title":"Cyclosporin A treatment of severe psoriasis","volume":"115","author":"Marks","year":"1986","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0666|cit666","first-page":"71","article-title":"Secukinumab is efficacious in clearing moderate-tosevere scalp psoriasis: 12 week results of a randomized phase IIIb study","volume":"58","author":"Mate","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0667|cit667","first-page":"86","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile through 5 years of treatment in moderate to severe psoriasis","volume":"59","author":"Mate","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub5-BIB0668|cit668","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1992","article-title":"Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical developmental programs","volume":"72","author":"McInnes","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0669|cit669","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0670|cit670","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0671|cit671","first-page":"1270","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase 3 study","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0672|cit672","first-page":"1169","article-title":"A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying antirheumatic drugs with active psoriatic arthritis","volume":"43","author":"Mease","year":"2016","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0673|cit673","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0674|cit674","first-page":"925","article-title":"52-week efficacy and safety results from SPIRIT-P1: a phase 3 study of ixekizumab in patients with active psoriatic arthritis","volume":"44","author":"Mease","year":"2017","journal-title":"Journal of Rheumatology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0675|cit675","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jid.2017.07.592","article-title":"Fifty-two-week efficacy and safety results from SPIRIT-P1: a phase 3 study of ixekizumab in patients with active psoriatic arthritis","volume":"137","author":"Mease","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0676|cit676","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0677|cit677","doi-asserted-by":"crossref","first-page":"AB165","DOI":"10.1016\/j.jaad.2020.06.749","article-title":"15964 Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis","volume":"83 6 Suppl","author":"Mease","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0678|cit678","first-page":"176","article-title":"Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate","volume":"146","author":"Meffert","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0679|cit679","first-page":"S33","article-title":"Single and multiple-dose pharmacokinetics of tofacitinib (CP-690,550) from a double-blind, placebo-controlled, dose-escalation study in medically stable subjects with psoriasis","volume":"91","author":"Menon","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0680|cit680","first-page":"AB174","article-title":"Efficacy of infliximab in patients with severe psoriasis: subgroup analysis from clinical trials","volume":"56","author":"Menter","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0681|cit681","first-page":"252","article-title":"Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions","volume":"13","author":"Menter","year":"2014","journal-title":"Journal of Drugs in Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0683|cit683","first-page":"16","article-title":"Ixekizumab improves nail and skin psoriasis through 52 weeks of treatment in patients with active psoriatic arthritis: results from two randomized, double-blind, phase 3, clinical trials (SPIRIT-P1 and SPIRIT-P2)","volume":"98","author":"Merola","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0684|cit684","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/jdv.16181","article-title":"Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis","volume":"34","author":"Merola","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0685|cit685","doi-asserted-by":"crossref","first-page":"AB118","DOI":"10.1016\/j.jaad.2020.06.560","article-title":"13350 Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis","volume":"83 6 Suppl","author":"Merola","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0686|cit686","first-page":"e17","article-title":"Immunogenicity of tumour necrosis factor inhibitors in patients with psoriasis receiving long-term treatment","volume":"165","author":"Meyer","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archdermatol.2009.5","article-title":"Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial","volume":"145","author":"Mittal","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0688|cit688","first-page":"48","article-title":"Efficacy of leflunomide in patients with psoriatic arthritis","volume":"10","author":"Moller","year":"2009","journal-title":"Seminarios de la Fundacion Espanola de Reumatologia"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0689|cit689","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2133.1986.tb05727.x","article-title":"Cyclosporin A and psoriasis","volume":"115","author":"Monk","year":"1986","journal-title":"British Journal of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0690|cit690","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1358\/dof.1993.018.10.222285","article-title":"BCX-34. Purine nucleoside phosphorylase (PNP) inhibitor","volume":"18","author":"Montgomery","year":"1993","journal-title":"Drugs of the Future"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0691|cit691","first-page":"25","article-title":"Low-dose ciclosporin A (sandimmun) in psoriasis: a multicenter dose-finding study","volume":"66","author":"Mrowietz","year":"1991","journal-title":"Zeitschrift fur Hautkrankheiten"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0692|cit692","first-page":"AB183","article-title":"Achievement of European Consensus Programme treatment goals in three clinical trials of adalimumab in moderate-to-severe psoriasis","volume":"66","author":"Mrowietz","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0693|cit693","first-page":"S36","article-title":"Serendipity opens new avenues: a pilot study to evaluate the efficacy of saxagliptin in combination with cyclosporine and acitretin in diabetic psoriasis patients","volume":"2","author":"Narang","year":"2012","journal-title":"Dermatology and Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0694|cit694","first-page":"42","article-title":"Secukinumab, a human anti-interleukin-17a monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial","volume":"45","author":"Nash","year":"2015","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0695|cit695","unstructured":"A study of the safety and effectiveness of infliximab in patients with plaque-type psoriasis clinicaltrials.gov\/ct2\/show\/NCT00106847"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0696|cit696","unstructured":"An evaluation of etanercept in the treatment of subjects with psoriasis clinicaltrials.gov\/ct2\/show\/nct00111111"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0697|cit697","unstructured":"A 36-week extension to protocol ISA04-03 clinicaltrials.gov\/ct2\/show\/NCT00258713"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0698|cit698","unstructured":"Long-term effects of infliximab in the treatment of moderate to severe psoriasis [extension of study P04271, NCT00251641] (P04563) clinicaltrials.gov\/ct2\/show\/nct00358670"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0699|cit699","unstructured":"The effectiveness of lower cyclosporine doses for psoriasis clinicaltrials.gov\/show\/nct00377325"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0700|cit700","unstructured":"Efficacy and safety of cyclosporine A microemulsion in maintenance patients with chronic plaque psoriasis clinicaltrials.gov\/show\/nct00438360"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0701|cit701","unstructured":"Study of tumor necrosis factor receptor fusion protein etanercept (enbrel) in psoriasis of the hands and\/or feet clinicaltrials.gov\/show\/nct00585650"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0702|cit702","unstructured":"Extension study of two dosing schedules of adalimumab in subjects with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct00645892"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0703|cit703","unstructured":"Study of the safety and efficacy of adalimumab in subjects with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct00646191"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0704|cit704","unstructured":"Adalimumab in adult Japanese subjects with psoriasis clinicaltrials.gov\/show\/nct00647400"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0705|cit705","unstructured":"Trial of an injectable biologic and U0279 as combination therapy for severe plaque-type psoriasis clinicaltrials.gov\/show\/nct00832364"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0706|cit706","unstructured":"A long term study to evaluate the safety and tolerability of CP-690,550 for patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/nct01163253"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0707|cit707","unstructured":"Evaluate efficacy, and safety of topical therapy and etanercept in subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct01235442"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0708|cit708","unstructured":"A study to assess the effect of ustekinumab (Stelara\u00ae) and etanercept (Enbrel\u00ae) in participants with moderate to severe psoriasis (MK-0000-206) clinicaltrials.gov\/show\/nct01276847"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0709|cit709","unstructured":"Efficacy and safety of intravenous and subcutaneous secukinumab in moderate to severe chronic plaque-type psoriasis (STATURE) clinicaltrials.gov\/show\/nct01412944"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0710|cit710","unstructured":"Study evaluating the efficacy and safety of triptergium wilfordii and acitretin in psoriasis vulgaris - CHINA201002016-2 clinicaltrials.gov\/show\/nct01443338"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0711|cit711","unstructured":"Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab clinicaltrials.gov\/show\/nct01544595"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0712|cit712","unstructured":"A study of ustekinumab to evaluate a \"subject-tailored\" maintenance dosing approach in subjects with moderate-to-severe plaque psoriasis (PSTELLAR) clinicaltrials.gov\/show\/nct01550744"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0713|cit713","unstructured":"A study in Japanese participants with moderate-to-severe psoriasis (UNCOVER-J) clinicaltrials.gov\/show\/nct01624233"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0714|cit714","unstructured":"Trial on the effect of adalimumab on vascular inflammation in patients with psoriasis clinicaltrials.gov\/show\/nct01722214"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0715|cit715","unstructured":"Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis (GESTURE) clinicaltrials.gov\/show\/nct01806597"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0716|cit716","unstructured":"Efficacy study on dimethyl fumarate to treat moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct01815723"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0717|cit717","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/jdv.17071","article-title":"First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis","volume":"35","author":"Kaul","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0718|cit718","unstructured":"Single and multiple dose escalation study to assess the safety and tolerability of CJM112 in psoriasis clinicaltrials.gov\/show\/nct01828086"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0719|cit719","unstructured":"A clinical research study of 28 weeks to test the safety\/tolerability and effectiveness of an investigational study medication (subcutaneous SCH 900222\/MK-3222) in improving the signs and symptoms of moderate-to-severe chronic plaque psoriasis, and to compare it to an approved medication for the treatment of psoriasis called etanercept www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-001740-54-HU"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0720|cit720","unstructured":"A study to evaluate the efficacy and safety\/tolerability of subcutaneous MK-3222 in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-012) clinicaltrials.gov\/show\/nct01936688"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0721|cit721","unstructured":"Secukinumab study in PSOriasis exploring pruRITUS intensity and lesional biomarkers (PSORITUS) clinicaltrials.gov\/show\/nct02362789"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0722|cit722","unstructured":"Plaque psoriasis efficacy and safety with secukinumab (OPTIMISE) clinicaltrials.gov\/show\/nct02409667"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0723|cit723","unstructured":"Study to evaluate the safety and efficacy of secukinumab 300 mg and 150 mg in adult patients with active psoriatic arthritis (PsA) after 16 weeks of treatment compared to placebo clinicaltrials.gov\/show\/nct02798211"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0724|cit724","unstructured":"Study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in patients with chronic plaque psoriasis clinicaltrials.gov\/show\/nct03010527"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0725|cit725","unstructured":"Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasis apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-002423-26-FI"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0726|cit726","unstructured":"Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct03020199"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0727|cit727","unstructured":"Study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in patients with chronic plaque psoriasis clinicaltrials.gov\/show\/nct03025542"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0728|cit728","unstructured":"A study of ixekizumab in Chinese participants with psoriasis vulgaris clinicaltrials.gov\/show\/nct03073213"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0729|cit729","unstructured":"The VOLTAIRE-X trial looks at the effect of switching between Humira\u00ae and BI 695501 in patients with plaque psoriasis clinicaltrials.gov\/show\/nct03210259"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0730|cit730","first-page":"AB126","article-title":"Efficacy, safety, and quality of life in patients with moderate-to-severe plaque psoriasis treated with mirikizumab (LY3074828) in a phase 2 study","volume":"79","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0731|cit731","unstructured":"A study to evaluate the efficacy and safety of mirikizumab (LY3074828) in participants with moderate-to-severe plaque psoriasis clinicaltrials.gov\/show\/nct03482011"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0732|cit732","unstructured":"A phase II clinical study of SHR-1314 injection in the treatment of moderate to severe plaque psoriasis in adults clinicaltrials.gov\/show\/NCT04121143"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0733|cit733","unstructured":"Efficacy, safety and PK of SHR-1314 in patients with moderate-to-severe plaque psoriasis clinicaltrials.gov\/show\/NCT04839016"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0734|cit734","unstructured":"A study of guselkumab in participants with active psoriatic arthritis clinicaltrials.gov\/show\/NCT04882098"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0735|cit735","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjd.16236","article-title":"Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study","volume":"178","author":"Nemoto","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0736|cit736","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000247856","article-title":"Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester","volume":"181","author":"Nieboer","year":"1990","journal-title":"Dermatologica"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0737|cit737","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/archderm.144.9.1200","article-title":"STROBE: a beacon for observational studies","volume":"144","author":"Nijsten","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0738|cit738","first-page":"S38","article-title":"Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital","volume":"131","author":"Noda","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0739|cit739","first-page":"4","article-title":"Efficacy and safety of methotrexate versus acitretin in chronic plaque psoriasis","volume":"31","author":"Noor","year":"2017","journal-title":"Journal of Postgraduate Medical Institute"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0740|cit740","first-page":"301","article-title":"Use of methotrexate in psoriasis","volume":"48","author":"Novotny","year":"1973","journal-title":"Ceskoslovenska Dermatologie"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0741|cit741","first-page":"208","article-title":"Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics","volume":"25","author":"Nyfors","year":"1978","journal-title":"Danish Medical Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0742|cit742","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1346-8138.14761","article-title":"Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study","volume":"46","author":"Okubo","year":"2019","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0743|cit743","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0744|cit744","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0745|cit745","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0028-1104405","article-title":"Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results)","volume":"103","author":"Orfanos","year":"1978","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0746|cit746","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2340\/0001555559241244","article-title":"Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis","volume":"59","author":"Orfanos","year":"1979","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0747|cit747","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/17469872.3.6.657","article-title":"Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL Study","volume":"3","author":"Ortonne","year":"2008","journal-title":"Expert Review of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0748|cit748","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","article-title":"Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE","volume":"25","author":"Ortonne","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0749|cit749","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jdermsci.2014.05.007","article-title":"Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study","volume":"75","author":"Osamu","year":"2014","journal-title":"Journal of Dermatological Science"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0750|cit750","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2019.11.027","article-title":"Molecular and cellular responses to the TYK2\/JAK1 inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis","volume":"140","author":"Page","year":"2020","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0751|cit751","first-page":"21","article-title":"RNA-seq genomic analysis demonstrated the molecular efficacy of risankizumab in a moderate-to-severe plaque psoriasis phase 2 clinical study","volume":"27","author":"Pakozdi","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0752|cit752","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1067\/mjd.2001.117850","article-title":"The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody","volume":"45","author":"Papp","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0753|cit753","first-page":"AB9","article-title":"A phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients","volume":"54","author":"Papp","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9521","key":"10.1002\/14651858.CD011535.pub5-BIB0754|cit754","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","article-title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0755|cit755","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2310\/7750.2009.00022","article-title":"Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies","volume":"13","author":"Papp","year":"2009","journal-title":"Journal of Cutaneous Medicine and Surgery"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0756|cit756","first-page":"AB153","article-title":"Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept","volume":"64","author":"Papp","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0757|cit757","first-page":"AB155","article-title":"Effects of abt-874 treatment on health-related quality of life and work productivity and activity impairment in patients with psoriasis","volume":"64","author":"Papp","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0758|cit758","first-page":"AB160","article-title":"Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874","volume":"64","author":"Papp","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0759|cit759","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546634.2013.861891","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","volume":"26","author":"Bushmakin","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0760|cit760","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0761|cit761","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/09546634.2014.906033","article-title":"Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses","volume":"26","author":"Mamolo","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0762|cit762","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0763|cit763","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0764|cit764","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","volume":"15","author":"Valenzuela","year":"2015","journal-title":"BMC Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0765|cit765","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial","volume":"132","author":"Papp","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0766|cit766","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0767|cit767","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0768|cit768","first-page":"54","article-title":"Effect of tildrakizumab on personal relationships in patients with moderate-to-severe chronic plaque psoriasis","volume":"98","author":"Papp","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0769|cit769","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jdv.14910","article-title":"Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial","volume":"32","author":"Papp","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0770|cit770","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-3083.2012.04611.x","article-title":"A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients","volume":"27","author":"Park","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0771|cit771","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1684\/ejd.2012.1863","article-title":"Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study","volume":"22","author":"Paul","year":"2012","journal-title":"European Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0772|cit772","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.12646","article-title":"Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)","volume":"170","author":"Paul","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0773|cit773","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jdv.14581","article-title":"Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials","volume":"32","author":"Paul","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0774|cit774","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5639\/gabij.2017.0604.042","article-title":"Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar","volume":"6","author":"Perks","year":"2017","journal-title":"GaBI Journal"},{"issue":"85 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0775|cit775","first-page":"133","article-title":"Oral retinoid for psoriasis. A report of a double blind study","volume":"59","author":"Pettit","year":"1979","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0776|cit776","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2133.1990.tb01481.x","article-title":"Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis","volume":"123","author":"Petzelbauer","year":"1990","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0777|cit777","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1331\/154434503322452328","article-title":"Alefacept, first biologic agent approved for treatment of psoriasis","volume":"43","author":"Piascik","year":"2003","journal-title":"Journal of the American Pharmacists Association"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0778|cit778","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0779|cit779","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaad.2017.10.025","article-title":"Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study","volume":"78","author":"Puig","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0780|cit780","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0781|cit781","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1358\/dot.2012.48.5.1811774","article-title":"A report from the American Academy of Dermatology 70th Annual Meeting (March 16-20, 2012; San Diego, California, USA)","volume":"48","author":"Rabasseda","year":"2012","journal-title":"Drugs of Today"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0782|cit782","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1365-4632.2011.04967.x","article-title":"Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial","volume":"50","author":"Radmanesh","year":"2011","journal-title":"International Journal of Dermatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0783|cit783","first-page":"S39","article-title":"Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis","volume":"16","author":"Raman","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0784|cit784","first-page":"808","article-title":"Alefacept in the treatment of psoriasis for whom conventional therapies are ineffective or inappropriate","volume":"18","author":"Reich","year":"2004","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0785|cit785","first-page":"AB192","article-title":"Evaluation of the efficacy and safety of alefacept in patients for whom conventional psoriasis therapies are ineffective or inappropriate","volume":"56","author":"Sclessinger","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0786|cit786","first-page":"AB150","article-title":"Long-term efficacy and safety of maintenance versus intermittent infliximab therapy for moderate to severe plaque-type psoriasis: the Restore2 trial","volume":"64","author":"Reich","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0787|cit787","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjd.12643","article-title":"One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis","volume":"170","author":"Reich","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"S1","key":"10.1002\/14651858.CD011535.pub5-BIB0788|cit788","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.14524","article-title":"LIBERATE trial: sustained efficacy of apremilast in patients with moderate-to-severe psoriasis who continued on apremilast or switched from etanercept treatment","volume":"175","author":"Reich","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"S4","key":"10.1002\/14651858.CD011535.pub5-BIB0789|cit789","first-page":"39","article-title":"Time course of ixekizumab drug levels and the relationship at week 60 to efficacy in patients with moderate-to- severe plaque psoriasis (UNCOVER-3)","volume":"25","author":"Reich","year":"2016","journal-title":"Experimental Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD011535.pub5-BIB0790|cit790","first-page":"627","article-title":"Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 in a phase 3B study","volume":"69","author":"Reich","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0791|cit791","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0792|cit792","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1111\/bjd.16059","article-title":"Safety of guselkumab in patients with plaque psoriasis through 2 years: a pooled analysis from VOYAGE 1 and VOYAGE 2","volume":"177","author":"Reich","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0793|cit793","unstructured":"Reich K Sullivan J Arenberger P Mrowietz U Jazayeri S Augustin M Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial British Journal of Dermatology 10.1111\/bjd.17351"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0794|cit794","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis","volume":"138","author":"Reich","year":"2018","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0795|cit795","first-page":"9","article-title":"Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial","volume":"27","author":"Reich","year":"2018","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0796|cit796","doi-asserted-by":"crossref","first-page":"AB147","DOI":"10.1016\/j.jaad.2020.06.677","article-title":"15328 Efficacy and safety of mirikizumab in patients with moderate to severe plaque psoriasis: 104-week results from a randomized phase 2 study","volume":"83 6 Suppl","author":"Bissonnette","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0797|cit797","article-title":"Patient-reported improvements in health-related quality of life by improvements in clinician-rated psoriasis severity: a phase 2 study analysis in patients with psoriasis treated with mirikizumab","volume":"12","author":"Gooderham","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0798|cit798","unstructured":"A study of mirikizumab (LY3074828) in participants with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct02899988"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0799|cit799","first-page":"S29","article-title":"Response to mirikizumab at week 52 among patients who did not achieve a PASI 90 response at week 16","volume":"12","author":"Papp","year":"2019","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0800|cit800","first-page":"e249","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a phase II study","volume":"177","author":"Reich","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0801|cit801","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study","volume":"181","author":"Reich","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0802|cit802","article-title":"Improvement in psoriasis scalp severity index (PSSI) during maintenance treatment with mirikizumab","volume":"12","author":"Rich","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0803|cit803","first-page":"978","article-title":"A double-blind study in patients with severe psoriasis to assess the clinical activity and safety of rapamycin (sirolimus) alone or in association with a reduced dose of cyclosporine","volume":"141","author":"Reitamo","year":"1999","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0804|cit804","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0805|cit805","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2165\/00128071-200304070-00006","article-title":"The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy","volume":"4","author":"Rim","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0806|cit806","first-page":"617","article-title":"Clinical efficacy of ciclosporin in the treatment of psoriasis: multicenter double blind study","volume":"7","author":"Clinical Study Group for Ciclosporin","year":"1991","journal-title":"Rincho Iyaku (Journal of Clinical Therapeutics and Medicines)"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0807|cit807","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11926-006-0059-6","article-title":"The efficacy and safety of adalimumab in psoriatic arthritis","volume":"8","author":"Ritchlin","year":"2006","journal-title":"Current Rheumatology Reports"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0808|cit808","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11926-006-0060-0","article-title":"The efficacy and safety of alefacept in psoriatic arthritis","volume":"8","author":"Ritchlin","year":"2006","journal-title":"Current Rheumatology Reports"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0809|cit809","doi-asserted-by":"crossref","first-page":"A807","DOI":"10.1016\/j.jval.2017.08.2409","article-title":"Ixekizumab treatment improves itching and health-related quality (HRQOL) of life in psoriasis patients in Latin America","volume":"20","author":"Romiti","year":"2017","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0810|cit810","unstructured":"Itolizumab for moderate-to-severe psoriasis-phase 3 registroclinico.sld.cu\/trials\/RPCEC00000201-En"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0811|cit811","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0812|cit812","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0813|cit813","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1365-2133.2006.07289.x","article-title":"Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"154","author":"Salim","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"41","key":"10.1002\/14651858.CD011535.pub5-BIB0814|cit814","first-page":"1806","article-title":"Treatment of psoriasis on an outpatient-base using UVB-radiations, oral retinoid and ten percent saline baths","volume":"70","author":"Scholl","year":"1981","journal-title":"Schweizerische Rundschau f\u00fcr Medizin Praxis"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0815|cit815","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1468-3083.1998.tb00975.x","article-title":"Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A","volume":"11","author":"Schopf","year":"1998","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0816|cit816","first-page":"33","article-title":"Comparative trial of sandimmune and etretinate for plaque-type psoriasis","volume":"66","author":"Schulze","year":"1991","journal-title":"Zeitschrift fur Hautkrankheiten"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0817|cit817","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1346-8138.2011.01228.x","article-title":"Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis","volume":"38","author":"Shintani","year":"2011","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0818|cit818","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/0190-9622(92)70224-4","article-title":"Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis","volume":"27","author":"Shiohara","year":"1992","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB0819|cit819","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0190-9622(97)80219-8","article-title":"Cyclosporine as maintenance therapy in patients with severe psoriasis","volume":"36","author":"Shupack","year":"1997","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0820|cit820","first-page":"60","article-title":"Psoriatic arthritis: combined treatment with prospidin and methotrexate","volume":"77","author":"Simonova","year":"2005","journal-title":"Terapevticheskii Arkhiv"},{"issue":"S1","key":"10.1002\/14651858.CD011535.pub5-BIB0821|cit821","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajd.12652","article-title":"Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: results from two randomised, controlled, phase 3 trials","volume":"58","author":"Sinclair","year":"2017","journal-title":"Australasian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0822|cit822","first-page":"e10","article-title":"Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis","volume":"165","author":"Sofen","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0823|cit823","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0824|cit824","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/ard.2007.085951","article-title":"Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis","volume":"67","author":"Spadaro","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0825|cit825","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjd.12025","article-title":"Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal","volume":"167","author":"Spuls","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0826|cit826","first-page":"221","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis: 52-week results of UNVEIL","volume":"17","author":"Stein Gold","year":"2018","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0827|cit827","first-page":"31","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"31","author":"Stein Gold","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0828|cit828","first-page":"50","article-title":"Therapy of severe psoriasis with Sandimmune","volume":"45","author":"Sticherling","year":"1994","journal-title":"Hautarzt (Symposium of Nurnberg Sandoz AG 13 February 1993, Nurnberg)"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0829|cit829","first-page":"270","article-title":"Etanercept for the treatment of psoriasis: combination therapy with other modalities","volume":"3","author":"Strober","year":"2004","journal-title":"Journal of Drugs in Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0830|cit830","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/bjd.12000","article-title":"Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label phase IIIB trial","volume":"167","author":"Strober","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0831|cit831","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2016.11.043","article-title":"Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept","volume":"76","author":"Strober","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0832|cit832","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study","volume":"16","author":"Strober","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0833|cit833","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1111\/bjd.16059","article-title":"Cytokine effects of apremilast as a mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: results from the UNVEIL trial","volume":"177","author":"Strober","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0834|cit834","first-page":"S21","article-title":"Efficacy and safety of apremilast in systemic- and biologic-naive patients with moderate plaque psoriasis (52-week results of the UNVEIL study)","volume":"11","author":"Strober","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0835|cit835","first-page":"706","article-title":"China-manufactured adalimumab biosimilar, HLX03, demonstrated pharmacokinetic equivalence and comparable safety to adalimumab","volume":"78 Suppl 2","author":"Sun","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0836|cit836","first-page":"AB224","article-title":"Subcutaneous administration of alefacept is bioequivalent to intramuscular administration: results of a randomized, open-label, crossover study in healthy volunteers","volume":"54","author":"Sweetser","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0837|cit837","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13063-019-3734-4","article-title":"Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)","volume":"21","author":"Syversen","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0838|cit838","first-page":"27","article-title":"Secukinumab improves anxiety and depression in patients with moderate-to-severe psoriasis: results from the SUPREME study","volume":"62 Suppl 1","author":"Talamonti","year":"2021","journal-title":"Australasian Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0839|cit839","first-page":"15","article-title":"Methotrexate-puvasol combination in treatment of psoriasis","volume":"58","author":"Talwar","year":"1992","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0840|cit840","unstructured":"Comparison of the clinical efficacy of subcutaneous versus oral administration of methotrexate in patients with psoriasis vulgaris www.who.int\/trialsearch\/Trial2.aspx?TrialID=TCTR20190705002"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0841|cit841","first-page":"S55","article-title":"Use of clinical trial data to compare psoriasis area and severity index, static physician's global assessment, and lattice system-physician's global assessment in assessing severity of psoriasis","volume":"2","author":"Tejasvi","year":"2012","journal-title":"Dermatology and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0842|cit842","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000066425","article-title":"Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study","volume":"205","author":"Tha\u00e7i","year":"2002","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0843|cit843","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","article-title":"A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study","volume":"163","author":"Tha\u00e7i","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD011535.pub5-BIB0844|cit844","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2340\/00015555-2978","article-title":"Certolizumab pegol improves patient-reported outcomes in chronic plaque psoriasis over 1 year","volume":"98","author":"Tha\u00e7i","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0845|cit845","first-page":"364","article-title":"Effectiveness observation on acitretin capsule for plaque psoriasis","volume":"17","author":"Tong","year":"2008","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine [xian Dai Zhong Xi Yi Jie He za Zhi]"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0846|cit846","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.16424","article-title":"Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal","volume":"179","author":"Tsakok","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0847|cit847","first-page":"22","article-title":"A phase II study of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in chronic plaque psoriasis","volume":"27","author":"Chimenti","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011535.pub5-BIB0848|cit848","first-page":"21","article-title":"A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes","volume":"27","author":"Kemeny","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"9959","key":"10.1002\/14651858.CD011535.pub5-BIB0849|cit849","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0850|cit850","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ad.2017.02.005","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study","volume":"108","author":"Valenzuela","year":"2017","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0851|cit851","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"Van de Kerkhof","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0852|cit852","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2133.1988.tb01772.x","article-title":"Low-dose cyclosporin A in severe psorasis. A double-blind study","volume":"118","author":"Van Joost","year":"1988","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0853|cit853","first-page":"575","article-title":"Evaluation of the efficacy and tolerability of a new intermittent treatment regimen with cyclosporin A in severe psoriasis","volume":"140","author":"Vena","year":"2005","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0854|cit854","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/09546634.2011.565017","article-title":"Combined treatment with low-dose cyclosporine and calcipotriol\/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study","volume":"23","author":"Vena","year":"2012","journal-title":"Journal of Dermatological Treatment"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0855|cit855","doi-asserted-by":"crossref","first-page":"509","DOI":"10.25259\/IJDVL_718_18","article-title":"Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis: a randomized controlled trial","volume":"87","author":"Verma","year":"2021","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0856|cit856","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000250882","article-title":"Oral retinoids and psoriasis","volume":"157","author":"Viglioglia","year":"1978","journal-title":"Dermatologica"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0857|cit857","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2133.1995.tb02500.x","article-title":"Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis","volume":"133","author":"Witkamp","year":"1995","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0858|cit858","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2133.2011.10616.x","article-title":"Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial","volume":"166","author":"Wolf","year":"2012","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0859|cit859","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archderm.1966.01600240097020","article-title":"Human low-dosage parenteral methotrexate therapy. A controlled toxicity study","volume":"93","author":"Wright","year":"1966","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0860|cit860","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4103\/0366-6999.151069","article-title":"Efficacy and safety of tripterygium wilfordii Hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial","volume":"128","author":"Wu","year":"2015","journal-title":"Chinese Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0861|cit861","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1684\/ejd.2011.1465","article-title":"Treatment of psoriasis with recombinant human LFA3-antibody fusion protein: a multi-center, randomized, double-blind trial in a Chinese population","volume":"21","author":"Yan","year":"2011","journal-title":"European Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0862|cit862","first-page":"59","article-title":"A prospective, double-blind, randomized controlled trial of folic acid supplementation vs. placebo in patients with chronic plaque psoriasis treated with methotrexate and effects on serum homocysteine","volume":"169","author":"Yesudian","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0863|cit863","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.18848","article-title":"Repurposing existing trial data to infer relative efficacy of biologics: guselkumab vs. ustekinumab for psoriasis","volume":"183","author":"Yiu","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0864|cit864","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/09546630701418747","article-title":"A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis","volume":"18","author":"Yoon","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0865|cit865","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jsxm.2018.09.004","article-title":"Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study","volume":"15","author":"Yosipovitch","year":"2018","journal-title":"Journal of Sexual Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0866|cit866","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Dermato-Venereologica"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0867|cit867","first-page":"592","article-title":"The effect of acitretin on moderate to severe plaque psoriasis","volume":"36","author":"Zhang","year":"2007","journal-title":"Journal of Clinical Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0868|cit868","first-page":"570","article-title":"A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis","volume":"48","author":"Zhang","year":"2009","journal-title":"Chung-Hua Nei Ko Tsa Chih (Chinese Journal of Internal Medicine)"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0869|cit869","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11655-009-0145-5","article-title":"Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type","volume":"15","author":"Zhang","year":"2009","journal-title":"Chinese Journal of Integrative Medicine"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0870|cit870","unstructured":"A study evaluating the efficacy and safety of CP-690,550 In Asian subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct01815424"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0871|cit871","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"Journal of Dermatological Science"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0872|cit872","first-page":"1730","article-title":"A multi-center, randomized, double-blind, placebo-controlled dose-ranging study evaluating efficacy and safety of SHR-1314 in subjects with moderate-to-severe plaque psoriasis","volume":"72 Suppl 10","author":"Zhang","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0873|cit873","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0874|cit874","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-016-2110-5","article-title":"First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis","volume":"72","author":"Zhuang","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0875|cit875","first-page":"102","article-title":"Cyclosporin is being tested for treatment of psoriasis","volume":"195","author":"Zobel","year":"1987","journal-title":"American Druggist"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0876|cit876","unstructured":"Phase III clinical trial to evaluate efficacy and safety of HS626 and remicade in patients with chronic moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000034243"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0877|cit877","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/jdv.13132","article-title":"Comparison of three methods for measuring psoriasis severity in clinical studies (part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment","volume":"29","author":"Chow","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0878|cit878","first-page":"e30","article-title":"Longitudinal effects of active therapy in a clinical trial on Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System-Physician's Global Assessment for assessing severity of psoriasis","volume":"165","author":"Chow","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB0879|cit879","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/jdv.12861","article-title":"Comparison of three methods for measuring psoriasis severity in clinical studies (part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment","volume":"29","author":"Simpson","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0880|cit880","unstructured":"Role of oral methotrexate, cyclosporine and acitretin in treatment of palmoplantar psoriasis (redcoloured, painful, itchy, fissured lesions on hands and feet) and psoriasis vulgaris (red coloured,scaly, itchy, elevated lesions on skin over body) ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=10246"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0881|cit881","unstructured":"A randomized, double-blind, placebo-controlled, comparative, prospective, multicentre trial to assess efficacy and safety of apremilast tablets in subjects with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=16164&EncHid=&modid=&compid=%27,%2716164det%27\/CTRI\/2016\/10\/007345"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0882|cit882","unstructured":"Comparison of ixekizumab with adalimumab in patients with psoriatic arthritis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2017\/09\/009850"},{"issue":"Suppl 245","key":"10.1002\/14651858.CD011535.pub5-BIB0883|cit883","first-page":"7S","article-title":"Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes","volume":"150","author":"Edwards","year":"2020","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0884|cit884","first-page":"ii10","article-title":"Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes","volume":"59 (Suppl 2)","author":"Edwards","year":"2020","journal-title":"Rheumatology (United Kingdom)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0885|cit885","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/annrheumdis-2020-eular.3996","article-title":"Head-to-head study evaluating the combined ACR50\/PASI100 treatment response of ixekizumab versus adalimumab: individual patient data from a randomized, openlabel study in biologic-naive patients with psoriatic arthritis through week 52","volume":"79","author":"Kavanaugh","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0886|cit886","first-page":"70","article-title":"Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study","volume":"183 (Suppl 1)","author":"Kleyn","year":"2020","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0887|cit887","first-page":"S140","article-title":"Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PSA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomized open-label study","volume":"27 (Suppl 1)","author":"Kristensen","year":"2021","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0888|cit888","first-page":"2723","article-title":"Efficacy of ixekizumab versus adalimumab in Psoriatic Arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study","volume":"72 (Suppl 10)","author":"Kristensen","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0889|cit889","first-page":"261","article-title":"Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week results","volume":"78 Suppl 2","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0890|cit890","first-page":"28","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"28","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0891|cit891","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0892|cit892","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaad.2020.06.137","article-title":"13771 Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate to severe psoriasis: 24-week results from a multicenter, randomized, open-label, rater-blinded study (SPIRIT-H2H)","volume":"83 (6 Suppl)","author":"Smith","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0893|cit893","first-page":"5266","article-title":"A head-to-head comparison of ixekizumab and adalimumab in biologic-na\u00efve patients with active psoriatic arthritis: efficacy and safety outcomes from a randomized, open-label, blinded assessor study through 52 weeks","volume":"71","author":"Smolen","year":"2019","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0894|cit894","first-page":"1437","article-title":"Patient-reported outcomes from a randomised, open-label, parallel-group study evaluating ixekizumab versus adalimumab in patients with PSA who are biologic DMARD na\u00efve: 24-week results","volume":"71","author":"Van Den Bosch","year":"2019","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0895|cit895","unstructured":"Study the efficacy and side effects of subcutaneous v\/s oral methotrexate in the management of moderate to severe psoriasis and palmoplantar psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/10\/028555"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0896|cit896","unstructured":"Regulatory T-cell function in psoriasis vulgaris www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000716"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0897|cit897","unstructured":"A randomised, double blind, placebo controlled efficacy and safety trial of different doses\/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-020168-39-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0898|cit898","unstructured":"A research study to evaluate the efficacy of LEO 32731 oral tablet formulation in patients with moderate to severe psoriasis vulgaris www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-005279-25-DE"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0899|cit899","first-page":"190","article-title":"Depression and anxiety in patients with moderate-to-severe plaque psoriasis while on methotrexate plus adalimumab vs. methotrexate monotherapy","volume":"181","author":"Goldust","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0900|cit900","first-page":"730","article-title":"Analysis of the effect of recombinant human tumor necrosis factor receptor in the treatment of moderate to severe plaque psoriasis on PASI score","volume":"36","author":"Han","year":"2007","journal-title":"Journal of Clinical Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0901|cit901","article-title":"Improvement in the quality of life of patients with severe plaque psoriasis treated with systemic methotrexate: a prospective, randomized, open-label, parallel group study in 60 patients","volume":"12","author":"Krishna","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association (Conference: 24th World Congress of Dermatology, Italy)"},{"issue":"S1","key":"10.1002\/14651858.CD011535.pub5-BIB0902|cit902","first-page":"65","article-title":"Improvement in the quality of life of patients with severe plaque psoriasis treated with systemic methotrexate in fixed doses of 10 mg or 25 mg orally once weekly: a prospective, randomized, double-blind, parallel-group study","volume":"175","author":"Krishna","year":"2016","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0903|cit903","unstructured":"Quality of life of patients with psoriasis treated with methotrexate: prospective, randomized, double-blind, parallel group study clinicaltrials.gov\/ct2\/show\/NCT02248792"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0904|cit904","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","article-title":"Effects of interleukin 17A Inhibition on myocardial deformation and vascular function in psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Canadian Journal of Cardiology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011535.pub5-BIB0905|cit905","first-page":"A69","article-title":"Dimethyl fumarate (BG00012) as an oral therapy for moderate to severe psoriasis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"125","author":"Mrowietz","year":"2005","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB0906|cit906","first-page":"187","article-title":"Results of a phase III study of a novel oral formulation of dimethylfumarate in the treatment of moderate to severe plaque psoriasis: efficacy, safety, and quality of life effects","volume":"19","author":"Mrowietz","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0907|cit907","unstructured":"Ortonne JP Van de Kerkhof P Mrowietz U A novel oral agent improves quality of life (QOL) in patients with plaque psoriasis 4th European Association of Dermatology and Venereology (EADV) Spring Symposium; 9-12 February 2006; Saariselka, Lapland, Finland 2006 P 013"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0908|cit908","unstructured":"The influence of adalimumab on cardiovascular and metabolic risk in psoriasis clinicaltrials.gov\/show\/nct01088165"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0909|cit909","unstructured":"A study to evaluate the effectiveness of STELARA \u2122 (USTEKINUMAB) in the treatment of scalp psoriasis clinicaltrials.gov\/ct2\/show\/NCT01558310"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0910|cit910","unstructured":"Comparison study of psoriasis severity assessment tools clinicaltrials.gov\/ct2\/show\/NCT02655705"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0911|cit911","unstructured":"Safety and efficacy study of etanercept (Qiangke\u00ae) to treat moderate to severe plaque psoriasis clinicaltrials.gov\/show\/nct02701205"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0912|cit912","unstructured":"A study to evaluate the similarity in efficacy and safety of mylan adalimumab (MYL-1401A) compared with humira\u00ae in subjects with moderate-to-severe chronic skin inflammatory disease www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-003420-46-BG"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0913|cit913","unstructured":"MYL-1401A efficacy and safety comparability study to humira\u00ae clinicaltrials.gov\/show\/nct02714322"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0914|cit914","unstructured":"Multicenter randomized double blind controlled-study to assess the potential of methotrexate versus placebo to improve and maintain response to anti TNF- alpha agents in adult patients with moderate to severe psoriasis clinicaltrials.gov\/show\/nct02829424"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0915|cit915","unstructured":"An efficacy study of secukinumab in plaque psoriasis patients with subclinical psoriatic arthritis as measured by musculoskeletal ultrasound (INTERCEPT) clinicaltrials.gov\/show\/NCT04488185"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0916|cit916","doi-asserted-by":"crossref","first-page":"AB88","DOI":"10.1016\/j.jaad.2021.06.375","article-title":"26197 Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil","volume":"85 3 Suppl","author":"Cestari","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0917|cit917","unstructured":"To compare the effect of three drugs- methotrexate, apremilast and their combination in patients suffering from psoriasis vulgaris www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2019\/07\/020274"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0918|cit918","unstructured":"A comparative clinical study to evaluate efficacy and safety of test drug in patients with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2020\/02\/023107"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB0919|cit919","doi-asserted-by":"crossref","first-page":"e039067","DOI":"10.1136\/bmjopen-2020-039067","article-title":"Randomised, double-blind, multicentre, phase I\/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol","volume":"10","author":"Dong","year":"2020","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0920|cit920","unstructured":"Influence of psychological factors on the response to therapy with secukinumab in psoriasis patients on the subjective and objective level www.who.int\/trialsearch\/Trial2.aspx?TrialID=DRKS00022104"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0921|cit921","first-page":"52 Erratum in:","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial","volume":"18","author":"Busard","year":"2017","journal-title":"Trials [Electronic Resource]"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0922|cit922","unstructured":"Optimising adalimumab treatment in psoriasis with concomitant methotrexate - OPTIMAP apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-004918-18-NL\/EUCTR2013-004918-18-NL"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0923|cit923","first-page":"25","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate: a randomized controlled trial","volume":"33","author":"Van Der Kraaij","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0924|cit924","unstructured":"A double-blind study in subjects with moderate to severe plaque psoriasis to evaluate efficacy, safety, tolerability of four different dose levels of ABY-035 compared to placebo www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-001615-36-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0925|cit925","unstructured":"A multicenter, double-blind, randomized, parallel-group, active control study to compare the efficacy, safety, and immunogenicity of AVT02 versus Humira\u00ae in patients with moderate-to-severe chronic plaque psoriasis (ALVOPAD PS) www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-003367-35-PL"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0926|cit926","unstructured":"A study to evaluate further therapeutic strategies with guselkumab in patients with moderate-to-severe plaque-type psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-001238-16-FR"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0927|cit927","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB0928|cit928","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2021-eular.1002","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 study","volume":"80","author":"Armstrong","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0929|cit929","unstructured":"Efficacy and safety of BMS-986165 versus placebo and active comparator in subjects with psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-001926-25-ES"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0930|cit930","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-184213"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0931|cit931","unstructured":"A study to investigate interchangeability of ABP 654 for the treatment of subjects with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-005205-42-DE"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB0932|cit932","doi-asserted-by":"crossref","first-page":"e047099","DOI":"10.1136\/bmjopen-2020-047099","article-title":"Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial","volume":"11","author":"Holsken","year":"2021","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0933|cit933","unstructured":"Therapeutic effects of adalimumab in patients with resistant psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT20120524009844N8"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0934|cit934","unstructured":"Safety and efficacy of etanercept in patients with psoriasis clinicaltrials.gov\/ct2\/show\/NCT02258282"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0935|cit935","unstructured":"Effect of brodalumab compared to placebo on vascular inflammation in moderate-to-severe psoriasis clinicaltrials.gov\/show\/nct03478280"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0936|cit936","unstructured":"Risankizumab therapy versus placebo for subjects with psoriasis in the Russian Federation (IMMPRESS) clinicaltrials.gov\/show\/nct03518047"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0937|cit937","unstructured":"A study to assess the safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE BRIGHT) clinicaltrials.gov\/show\/nct03598790"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0938|cit938","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis clinicaltrials.gov\/show\/nct03611751"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0939|cit939","unstructured":"Efficacy and safety study of tildrakizumab in the treatment of nail psoriasis clinicaltrials.gov\/show\/nct03897075"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0940|cit940","unstructured":"Efficacy and safety of tildrakizumab in the treatment of scalp psoriasis clinicaltrials.gov\/show\/nct03897088"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0941|cit941","unstructured":"Efficacy and safety of SCT630 and adalimumab (HUMIRA\u00ae) in adults with plaque psoriasis clinicaltrials.gov\/show\/nct03927352"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0942|cit942","unstructured":"Efficacy and safety study of hemay005 in subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04102241"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0943|cit943","unstructured":"An investigational study to evaluate experimental medication BMS-986165 compared to placebo in participants with plaque psoriasis in mainland China, Taiwan, and South Korea (POETYK-PSO-3) clinicaltrials.gov\/show\/NCT04167462"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0944|cit944","unstructured":"Study in patients with plaque psoriasis with coexisting non-alcoholic fatty liver disease www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-003168-37-DE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0945|cit945","unstructured":"A study of secukinumab treatment in patients with plaque psoriasis and coexisting Non-Alcoholic Fatty Liver Disease (NAFLD) (pINPOINt) clinicaltrials.gov\/show\/NCT04237116"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0946|cit946","unstructured":"Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and \u2265120 kg body weight www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-004998-13-FR"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0947|cit947","unstructured":"Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and \u2265120 kg body weight clinicaltrials.gov\/show\/NCT04306315"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0948|cit948","unstructured":"An explorative psoriasis biomarker study www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-002383-27-NL"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0949|cit949","unstructured":"An explorative psoriasis biomarker study clinicaltrials.gov\/show\/NCT04394936"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0950|cit950","unstructured":"Multicenter, double-blind, randomized, parallel-group, study evaluating pharmacokinetic, efficacy, safety, and immunogenicity between patients with moderate to severe chronic plaque psoriasis receiving humira\u00ae and patients undergoing repeated switches between humira\u00ae and AVT02 followed by a safety extension phase of AVT02 www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-002911-25-PL"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0951|cit951","unstructured":"Pharmacokinetic, efficacy, safety, and immunogenicity of AVT02 with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/NCT04453137"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0952|cit952","unstructured":"Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab (COBRA) clinicaltrials.gov\/show\/NCT04533737"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0953|cit953","unstructured":"A double-blind study to compare the efficacy, safety, and immunogenicity of the proposed biosimilar ustekinumab FYB202 to stelara in patients with moderate-to-severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-004364-21-PL"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0954|cit954","unstructured":"A double-blind study to compare the efficacy, safety, and immunogenicity of the proposed biosimilar ustekinumab FYB202 to stelara\u00ae in patients with moderate-to-severe plaque psoriasis (VESPUCCI) clinicaltrials.gov\/show\/NCT04595409"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0955|cit955","unstructured":"A study to investigate ABP 654 for the treatment of subjects with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-003184-25-EE"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0956|cit956","unstructured":"A study to investigate ABP 654 for the treatment of participants with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04607980"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0957|cit957","unstructured":"A phase 4 study of brodalumab (KHK4827) in subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04614298"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0958|cit958","unstructured":"A phase 3 study to compare the efficacy and safety of CT-P43 to stelara in patients with plaque psoriasis clinicaltrials.gov\/show\/NCT04673786"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0959|cit959","unstructured":"Study of subcutaneous (injected under the skin) risankizumab to assess change in disease symptoms in adult participants with moderate to severe plaque psoriasis with palmoplantar involvement clinicaltrials.gov\/show\/NCT04713592"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0960|cit960","unstructured":"Comparative study of BAT2206 with stelara\u00ae in patients with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04728360"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0961|cit961","unstructured":"Clinical study comparing DMB-3115 and stelara\u00ae in patients with moderate to severe chronic plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-005108-21-HU"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0962|cit962","unstructured":"Efficacy, safety, and immunogenicity of subcutaneous DMB-3115 versus stelara\u00ae in patients with moderate to severe chronic plaque psoriasis clinicaltrials.gov\/show\/NCT04785326"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0963|cit963","unstructured":"A phase \u2162 efficacy and safety study of hemay005 in subjects with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04839328"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0964|cit964","unstructured":"Study of subcutaneous risankizumab injection compared to oral apremilast tablets to assess change in disease activity and adverse events in adult participants with moderate plaque psoriasis who are candidates for systemic therapy clinicaltrials.gov\/show\/NCT04908475"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0965|cit965","unstructured":"A study of guselkumab (TREMFYA) in Chinese participants with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04914429"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0966|cit966","unstructured":"Efficacy, safety, and immunogenicity of AVT04 with moderate-to-severe chronic plaque psoriasis clinicaltrials.gov\/show\/NCT04930042"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0967|cit967","unstructured":"SB17 versus stelara\u00ae in subjects with moderate to severe plaque psoriasis www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2020-006115-19-CZ"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0968|cit968","unstructured":"A study to compare SB17 (proposed ustekinumab biosimilar) to stelara\u00ae in subject with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT04967508"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0969|cit969","unstructured":"Multi-center PAMPA study clinicaltrials.gov\/show\/NCT05004727"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0970|cit970","unstructured":"A study to evaluate the efficacy and safety of bimekizumab in adult Korean study participants with moderate to severe plaque psoriasis clinicaltrials.gov\/show\/NCT05020249"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0971|cit971","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.19244","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis","volume":"184","author":"Afach","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0972|cit972","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0973|cit973","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatology"},{"issue":"19","key":"10.1002\/14651858.CD011535.pub5-BIB0974|cit974","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB0975|cit975","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010497.pub2","article-title":"Oral fumaric acid esters for psoriasis","author":"Atwan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0976|cit976","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.14500","article-title":"Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies","volume":"175","author":"Balak","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0977|cit977","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0978|cit978","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18553\/jmcp.2021.27.1.084","article-title":"Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review","volume":"27","author":"Blauvelt","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0979|cit979","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB0980|cit980","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB0981|cit981","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/jamadermatol.2018.1165","article-title":"Identifying a core domain set to assess psoriasis in clinical trials","volume":"154","author":"Callis Duffin","year":"2018","journal-title":"JAMA Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0982|cit982","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14712598.2017.1283401","article-title":"Certolizumab pegol for the treatment of psoriasis","volume":"17","author":"Campanati","year":"2017","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB0983|cit983","doi-asserted-by":"crossref","first-page":"E2526","DOI":"10.3390\/ijms18122526","article-title":"The genetic basis of psoriasis","volume":"18","author":"Capon","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0984|cit984","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0985|cit985","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ije\/dyt074","article-title":"Effects of study precision and risk of bias in networks of interventions: a network meta-epidemiological study","volume":"42","author":"Chaimani","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"S0895","key":"10.1002\/14651858.CD011535.pub5-BIB0986|cit986","first-page":"30775","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"16","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0987|cit987","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.11.015","article-title":"Additional considerations are required when preparing a protocol for a systematic review with multiple interventions","volume":"83","author":"Chaimani","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB0988|cit988","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/eb-2017-102753","article-title":"Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article","volume":"20","author":"Chaimani","year":"2017","journal-title":"Evidence-Based Mental Health"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB0989|cit989","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB0990|cit990","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study","volume":"26","author":"Christophers","year":"1992","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0991|cit991","unstructured":"Institute of Social and Preventive Medicine, University of Bern CINeMA: Confidence in Network Meta-Analysis 2017"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0992|cit992","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0993|cit993","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0994|cit994","unstructured":"Veritas Health Innovation Covidence 2014"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0995|cit995","first-page":"f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD011535.pub5-BIB0996|cit996","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"7-8","key":"10.1002\/14651858.CD011535.pub5-BIB0997|cit997","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB0998|cit998","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jcpt.13153","article-title":"Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis","volume":"45","author":"D\u00edaz Acedo","year":"2020","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB0999|cit999","first-page":"123","article-title":"New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors","volume":"99","author":"Dong","year":"2017","journal-title":"Cutis"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1000|cit1000","doi-asserted-by":"crossref","first-page":"123","DOI":"10.36469\/jheor.2020.13671","article-title":"A systematic literature review and bucher indirect comparison: tildrakizumab versus guselkumab","volume":"7","author":"Du Jardin","year":"2020","journal-title":"Journal of Health Economics and Outcomes Research"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1001|cit1001","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/jid.2009.319","article-title":"Molecular dissection of psoriasis: integrating genetics and biology","volume":"130","author":"Elder","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1002|cit1002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.08.010","article-title":"Living systematic review: 1. Introduction-the why, what, when, and how","volume":"91","author":"Elliott","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB1003|cit1003","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s13555-021-00602-z","article-title":"Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis","volume":"11","author":"Fahrbach","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1004|cit1004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1568010043343903","article-title":"Targeting tumor necrosis factor-alpha in the therapy of psoriasis","volume":"3","author":"Gisondi","year":"2004","journal-title":"Current Drug Targets. Inflammation and Allergy"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1005|cit1005","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjd.14814","article-title":"Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"176","author":"G\u00f3mez-Garc\u00eda","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011535.pub5-BIB1006|cit1006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3310\/hta13Suppl3-10","article-title":"Ustekinumab for the treatment of moderate to severe psoriasis","volume":"13","author":"Gospodarevskaya","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"9583","key":"10.1002\/14651858.CD011535.pub5-BIB1007|cit1007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1008|cit1008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jdv.16566","article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database","volume":"35","author":"Grodner","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1009|cit1009","unstructured":"Guelimi R Afach S Bettuzzi T Chaby G Sbidian E Overlapping network meta-analyses on psoriasis systemic treatments: an\u00a0overview,\u00a0quantity does not make quality British Journal of Dermatology 10.1111\/bjd.20908"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB1010|cit1010","first-page":"ii3","article-title":"Classification and diagnostic criteria for psoriatic arthritis","volume":"64","author":"Helliwell","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1011|cit1011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1012|cit1012","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD011535.pub5-BIB1013|cit1013","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1014|cit1014","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group","volume":"141","author":"Ho","year":"1999","journal-title":"British Journal of Dermatology"},{"issue":"21","key":"10.1002\/14651858.CD011535.pub5-BIB1015|cit1015","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD011535.pub5-BIB1016|cit1016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00403-007-0775-4","article-title":"The role of dendritic cells in the immunopathogenesis of psoriasis","volume":"299","author":"Jariwala","year":"2007","journal-title":"Archives of Dermatological Research"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB1017|cit1017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"American Journal of Clinical Dermatology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB1018|cit1018","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1019|cit1019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial","volume":"162","author":"Lebwohl","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1020|cit1020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109358","article-title":"Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials","volume":"216","author":"Le Cleach","year":"2008","journal-title":"Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1021|cit1021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2019.08.006","article-title":"Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting","volume":"121","author":"Liang","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB1022|cit1022","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/2013.jamadermatol.238","article-title":"Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis","volume":"148","author":"Lin","year":"2012","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1023|cit1023","unstructured":"Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode Available from community.cochrane.org\/review-production\/production-resources\/living-systematic-reviews#guidance"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011535.pub5-BIB1024|cit1024","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3310\/hta13suppl1-09","article-title":"Infliximab for the treatment of adults with psoriasis","volume":"13","author":"Loveman","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1025|cit1025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1026|cit1026","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1027|cit1027","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1028|cit1028","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005028.pub3","article-title":"Topical treatments for chronic plaque psoriasis","author":"Mason","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1029|cit1029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/eb-2014-101900","article-title":"Addressing missing outcome data in meta-analysis","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1030|cit1030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25 Suppl 2","author":"Maza","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1031|cit1031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25 Suppl 2","author":"Montaudie","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1032|cit1032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000232307","article-title":"Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab","volume":"38","author":"Mossner","year":"2009","journal-title":"Current Problems in Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1033|cit1033","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/0190-9622(95)91393-9","article-title":"Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study","volume":"33","author":"Mrowietz","year":"1995","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1034|cit1034","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.17130","article-title":"Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values \u2264 1, 2, 3 or 5 derived from a statistical conversion method","volume":"35","author":"Mrowietz","year":"2021","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1035|cit1035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clindermatol.2009.03.001","article-title":"Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clinics in Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD011535.pub5-BIB1036|cit1036","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"135","author":"Nast","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB1037|cit1037","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/jdv.13353","article-title":"Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris - update 2015--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1038|cit1038","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaad.2007.09.018","article-title":"Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period","volume":"58","author":"Nelson","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB1039|cit1039","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archderm.143.9.1113","article-title":"Clinical severity of psoriasis in last 20 years of PUVA study","volume":"143","author":"Nijsten","year":"2007","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1040|cit1040","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jclinepi.2021.01.006","article-title":"An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials","volume":"133","author":"Noel-Storr","year":"2021","journal-title":"Journal of Clinical Epidemiology\u00a0"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1041|cit1041","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.0007-0963.2004.05903.x","article-title":"Fumaric acid esters, their place in the treatment of psoriasis","volume":"150","author":"Ormerod","year":"2004","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1042|cit1042","first-page":"m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ (Clinical research ed.)"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD011535.pub5-BIB1043|cit1043","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1044|cit1044","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1185\/030079908X291985","article-title":"Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis","volume":"24","author":"Reich","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1045|cit1045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1046|cit1046","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2020"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1047|cit1047","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ (Clinical research ed.)"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1048|cit1048","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB1049|cit1049","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1050|cit1050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the treatment of psoriasis and psoriatic arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1051|cit1051","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jdv.15277","article-title":"Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"33","author":"Sawyer","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1052|cit1052","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2011.03993.x","article-title":"Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review","volume":"25 Suppl 2","author":"Sbidian","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1053|cit1053","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1054|cit1054","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD011535.pub5-BIB1055|cit1055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1056|cit1056","doi-asserted-by":"crossref","first-page":"e13802","DOI":"10.1111\/dth.13802","article-title":"A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis","volume":"33","author":"Shi","year":"2020","journal-title":"Dermatologic Therapy"},{"issue":"10","key":"10.1002\/14651858.CD011535.pub5-BIB1057|cit1057","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1058|cit1058","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.13437","article-title":"Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response","volume":"172","author":"Signorovitch","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1059|cit1059","doi-asserted-by":"crossref","first-page":"308","DOI":"10.5414\/CP203831","article-title":"Relative efficacy and safety of tofacitinib for\u00a0treating psoriasis: a Bayesian network meta-analysis of randomized controlled trials","volume":"59","author":"Song","year":"2021","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB1060|cit1060","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1046\/j.1365-2133.1997.19902071.x","article-title":"A systematic review of five systemic treatments for severe psoriasis","volume":"137","author":"Spuls","year":"1997","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1061|cit1061","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review","volume":"130","author":"Spuls","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1062|cit1062","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"Journal of Investigative Dermatology (Symposium proceedings)"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB1063|cit1063","first-page":"1442","article-title":"Conventional systemic agents for psoriasis. A systematic review","volume":"33","author":"Strober","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1064|cit1064","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","article-title":"Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"99","author":"Tada","year":"2020","journal-title":"Journal of Dermatological Science"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB1065|cit1065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/09546634.2010.487890","article-title":"Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: a meta-analysis","volume":"22","author":"Tan","year":"2011","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1066|cit1066","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ddr.21263","article-title":"Small molecules in the treatment of psoriasis","volume":"76","author":"Torres","year":"2015","journal-title":"Drug Development Research"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1067|cit1067","doi-asserted-by":"crossref","unstructured":"Torres T Barcelos A Filipe P Fonseca JE A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains Frontiers in Medicine 2020 7 618163 33521024","DOI":"10.3389\/fmed.2020.618163"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB1068|cit1068","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011535.pub5-BIB1069|cit1069","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3310\/hta13suppl2-07","article-title":"Adalimumab for the treatment of psoriasis","volume":"13","author":"Turner","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1070|cit1070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1071|cit1071","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jclinepi.2018.02.009","article-title":"Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?","volume":"100","author":"Veroniki","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011535.pub5-BIB1072|cit1072","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","article-title":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16\u00a0weeks: results from a network meta-analysis","volume":"82","author":"Warren","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1073|cit1073","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13555-019-00337-y","article-title":"Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using bayesian and frequentist network meta-analyses","volume":"10","author":"Warren","year":"2020","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1074|cit1074","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"9","key":"10.1002\/14651858.CD011535.pub5-BIB1075|cit1075","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nature Immunology"},{"issue":"46","key":"10.1002\/14651858.CD011535.pub5-BIB1076|cit1076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10460","article-title":"Etanercept and efalizumab for the treatment of psoriasis: a systematic review","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1077|cit1077","first-page":"47","article-title":"Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis","volume":"19","author":"Xu","year":"2021","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft (Journal of the German Society of Dermatology : JDDG)"},{"issue":"6","key":"10.1002\/14651858.CD011535.pub5-BIB1078|cit1078","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/1203475420933174","article-title":"Efficacy of brodalumab for moderate to severe plaque psoriasis: a Canadian network meta-analysis","volume":"24","author":"Xue","year":"2020","journal-title":"Journal of Cutaneous Medicine and Surgery"},{"key":"10.1002\/14651858.CD011535.pub5-BIB1079|cit1079","unstructured":"Yasmeen N Sawyer LM Malottki K Didriksen Apol E Jemec GB Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year Journal of Dermatological Treatment 10.1080\/09546634.2020.1743811"},{"issue":"7","key":"10.1002\/14651858.CD011535.pub5-BIB1080|cit1080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","article-title":"Prevalence of joint disease in patients with psoriasis: implications for therapy","volume":"4","author":"Zachariae","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"issue":"7128","key":"10.1002\/14651858.CD011535.pub5-BIB1081|cit1081","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1002\/14651858.CD011535.pub5-BIB1082|cit1082","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis","author":"Sbidian","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD011535.pub5-BIB1083|cit1083","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011535.pub5-BIB1084|cit1084","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011535.pub5-BIB1085|cit1085","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd011535.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:14:35Z","timestamp":1700619275000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011535.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":1085,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011535.pub5","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD011535.pub6","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}